

Objection Deadline: October 27, 2020 @ 12:00 p.m. (ET)

**UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK**

In re:	Chapter 11
PURDUE PHARMA L.P., <i>et al.</i> , ¹	Case No. 19-23649 (RDD)
Debtors.	(Jointly Administered)

**TWELFTH MONTHLY FEE STATEMENT OF ALIXPARTNERS, LLP,
FINANCIAL ADVISOR TO THE CHAPTER 11 DEBTORS FOR
ALLOWANCE OF COMPENSATION FOR SERVICES
RENDERED AND FOR REIMBURSEMENT OF EXPENSES
FOR THE PERIOD OF AUGUST 1, 2020 THROUGH AUGUST 31, 2020**

Name of Applicant:	ALIXPARTNERS, LLP	
Applicant’s Role in Case:	Financial Advisor to the Chapter 11 Debtors	
Date Order of Employment Signed:	November 21, 2019 [Docket No. 528], <i>Nunc Pro Tunc</i> to September 15, 2019	
Time period covered by this statement:	Beginning of Period	End of Period
	August 1, 2020	August 31, 2020
Summary of Total Fees and Expenses Requested:		
Total fees requested in this statement:	\$778,392.80 (80% of \$972,991.00)	
Total expenses requested in this statement:	\$327.22	
Total fees and expenses requested in this statement:	\$778,720.02	
This is a(n): <u> X </u> Monthly Application <u> </u> Interim Application <u> </u> Final Application		

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY PROFESSIONAL
FOR THE PERIOD AUGUST 1, 2020 THROUGH AUGUST 31, 2020**

PROFESSIONAL	TITLE	RATE	HOURS	FEES
Lisa Donahue	Managing Director	\$1,195	19.8	\$ 23,661.00
Richard Collura	Managing Director	\$1,090	48.1	52,429.00
Jesse DelConte	Director	\$950	162.3	154,185.00
Kevin M McCafferty	Director	\$950	206.2	195,890.00
Mark F Rule	Director	\$910	35.4	32,214.00
Gabe J Koch	Director	\$840	128.8	108,192.00
HS Bhattal	Director	\$840	29.8	25,032.00
Elizabeth S Kardos	Director	\$710	5.2	3,692.00
Isabel Arana de Uriate	Senior Vice President	\$690	1.2	828.00
Sam J Canniff	Senior Vice President	\$645	136.1	87,784.50
Kristina Galbraith	Senior Vice President	\$645	7.3	4,708.50
Fernando O Silva	Senior Vice President	\$645	8.4	5,418.00
Laurie C Verry	Senior Vice President	\$510	4.1	2,091.00
Andrew D DePalma	Vice President	\$515	207.3	106,759.50
Sam K Lemack	Vice President	\$515	183.2	94,348.00
Nate A Simon	Vice President	\$515	116.3	59,894.50
Tammy Brewer	Vice President	\$450	2.6	1,170.00
Melanie McCabe	Vice President	\$415	6.0	2,490.00
Andrea M LeBar	Associate	\$375	10.2	3,825.00
Mary B Betik	Paraprofessional	\$315	10.0	3,150.00
Barbara J Ferguson	Paraprofessional	\$315	16.6	5,229.00
Total Professional Hours and Fees			1,344.9	\$ 972,991.00
Less 50% Travel Fees				-
Subtotal				\$ 972,991.00
Less 20% Holdback				(194,598.20)
Invoice Total				\$ 778,392.80
			Average Billing Rate	\$ 723.47

ALIXPARTNERS, LLP

SUMMARY OF HOURS AND FEES BY MATTER CATEGORY
FOR THE PERIOD AUGUST 1, 2020 THROUGH AUGUST 31, 2020

CODE	MATTER CATEGORY	HOURS	FEES
101	Chapter 11 Process/Case Management	54.5	\$ 48,177.00
103	Cash Management	157.5	86,135.00
104	Communication with Interested Parties	61.0	35,243.00
105	U.S. Trustee / Court Reporting Requirements	5.2	3,113.00
106	Business Analysis & Operations	632.7	510,961.50
107	POR Development	29.0	18,506.50
108	Executory Contracts	0.8	629.50
109	Claims Process	50.8	24,003.50
110	Special Projects	87.2	45,944.00
113	Fee Statements and Fee Applications	38.6	23,243.00
114	Court Hearings	3.7	3,121.50
115	Forensic Analysis	223.9	173,913.50
		1,344.9	\$ 972,991.00
		Average Billing Rate	\$ 723.47

ALIXPARTNERS, LLP

SUMMARY OF EXPENSES
FOR THE PERIOD AUGUST 1, 2020 THROUGH AUGUST 31, 2020

EXPENSE CATEGORY	EXPENSE
Legal Fees	\$ 70.00
Other	257.22
Total	\$ 327.22

AlixPartners, LLP (“AlixPartners”), as financial advisor to the Debtors and its affiliated Debtors, (collectively, the “Debtors”), hereby submits this Twelfth Monthly Fee Statement seeking compensation for professional services rendered and reimbursement of out-of-pocket expenses for the period August 1, 2020 through August 31, 2020 (the “Compensation Period”), pursuant to the *Order Establishing Procedures For Interim Compensation and Reimbursement of Expenses for Retained Professionals* [Docket No. 528] and the *Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as its Financial Advisor Nunc Pro Tunc to the September 16, 2019* [Docket No. 528].

Detailed time descriptions of the services performed by each professional, organized by discrete project and by day is attached hereto as **Exhibit A**. Exhibit A (a) identifies the individuals that rendered services in each subject matter; (b) describes each activity or service that each individual performed; and (c) states the number of hours (in tenths of an hour) spent by each individual providing the services during the Compensation Period.

A detailed analysis of the out-of-pocket expenses showing the amount incurred by each professional in each expense category by day is attached hereto as **Exhibit B**.

WHEREFORE, AlixPartners respectfully requests that it be granted an allowance of compensation for professional services rendered during the Compensation Period in the amount of \$972,991.00, without prejudice to a final allowance of compensation, plus reimbursement of actual and necessary out-of-pocket expenses incurred in the amount of \$327.22, and that the Court grant AlixPartners such other and further relief as is just and proper. Pursuant to the Interim Compensation Order, AlixPartners seeks payment of professional fees in the amount of \$778,392.80 (80% of \$972,991.00) and expenses in the amount of \$327.22, for a total amount of \$778,720.02.

Dated: October 13, 2020

ALIXPARTNERS, LLP
909 Third Avenue, 28th Floor
New York, NY 10022

/s/ Lisa Donahue

By: Lisa Donahue
Managing Director

Exhibit A

AlixPartners, LLP

Detailed Description of AlixPartners' Fees and Hours by Matter Category

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
08/03/20	JD	Review and provide comments on draft KEIP / KERP motion.	0.60
08/04/20	JD	Weekly catch up call with M. Huebner, C. Robertson (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	0.60
08/04/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: post weekly professionals call planning.	0.50
08/04/20	HSB	Weekly catch up call with M. Huebner, C. Robertson (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	0.60
08/04/20	LJD	Prepare for and attend weekly catch up call with M. Huebner, C. Robertson (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	0.70
08/04/20	GJK	Weekly catch up call with M. Huebner, C. Robertson (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	0.60
08/06/20	LJD	Prepare for and attend call with J. DelConte, L. Donahue, H. Bhattal (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: case update and go forward planning.	0.90
08/06/20	HSB	Call with J. DelConte, L. Donahue, H. Bhattal (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), C. Landau, M. Kesselman, J. Lowne,	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
08/06/20	JD	R. Aleali (all Purdue) re: case update and go forward planning. Call with J. DelConte, L. Donahue, H. Bhattal (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: case update and go forward planning.	0.70
08/06/20	JD	Calls with D. Consla (Davis Polk) re: KEIP/KERP motion.	0.90
08/07/20	JD	Call with D. Consla, E. Vonnegut and S. Brecher (all Davis Polk) re: KEIP/KERP motion.	0.20
08/07/20	JD	Call with S. Brecher, D. Consla (both Davis Polk), S. Hinden, D. Sims, J. Gartrell (all Willis Towers Watson), C. DiStefano, R. Aleali, K. Laurel (all Purdue) re: KEIP/KERP motion drafting.	3.20
08/07/20	HSB	Review agreed order among the UCC, the non-consenting states group and the debtors re: discovery in the Ch 11 Cases.	0.40
08/07/20	HSB	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	LJD	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	MFR	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	FOS	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
08/07/20	SKL	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	SJC	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	NAS	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	GJK	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/10/20	JD	Correspondence with C. Oluwole (Davis Polk), R. Collura and G. Koch (AlixPartners) re: Sackler transfers call.	0.40
08/11/20	JD	Review latest transfer trust checklist prior to call.	0.70
08/11/20	JD	Weekly catch up call with L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners), M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT) re: weekly catch up on case progress.	0.80
08/11/20	HSB	Update call with L. Donahue, J. DelConte, G. Koch, (all AlixPartners), J. McClammy, E. Vonnegut, B. Kaminetzky, T. Graulich, C. Robertson (all Davis Polk), J. O'Connell, T. Coleman, J. Turner (all PJT Partners).	0.80
08/11/20	GJK	Update Debtor professionals on weekly advisor coordinating call re: IACs.	0.80
08/11/20	LJD	Prepare for and attend weekly advisors call	0.90
08/12/20	JD	Review and provide comments on agenda for tomorrow's call.	0.30
08/12/20	JD	Review comments to draft Mundipharma email from the	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		UCC and AHC. Provide comments re: same.	
08/13/20	JD	Call with J. Lowne, R. Aleali (both Purdue), J. O'Connell, T. Melvin, G. Sim (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and planning call.	0.90
08/13/20	JD	Attend Sackler distribution history meeting with AHC professionals, UCC professionals, L. Donahue, G. Koch, R. Collura, J. DelConte (all AlixPartners), PJT, Davis Polk and Dechert.	0.70
08/13/20	JD	Review Sackler cash and non-cash activity report shared on the conference call.	1.20
08/13/20	LJD	Attend Sackler distribution history meeting with AHC professionals, UCC professionals, L. Donahue, G. Koch, R. Collura, J. DelConte (all AlixPartners), PJT, Davis Polk and Dechert.	0.70
08/13/20	GJK	Attend Sackler distribution history meeting with AHC professionals, UCC professionals, L. Donahue, G. Koch, R. Collura, J. DelConte (all AlixPartners), PJT, Davis Polk and Dechert.	0.70
08/13/20	RC	Attend Sackler distribution history meeting with AHC professionals, UCC professionals, L. Donahue, G. Koch, R. Collura, J. DelConte (all AlixPartners), PJT, Davis Polk and Dechert.	0.70
08/14/20	GJK	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	LJD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
08/14/20	SKL	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	NAS	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	SJC	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	JD	Create agenda for weekly AlixPartners update call.	0.40
08/14/20	JD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	JD	Correspondence with Davis Polk and PJT re: distributable value and insurance proceeds.	0.40
08/14/20	HSB	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	ADD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	ADD	Prepare for AlixPartners Purdue engagement team update meeting.	0.50
08/17/20	HSB	Review sale scenario valuation summary prepared by PJT Partners.	0.30
08/17/20	HSB	Review Avrio section of the April financial statement presentation with financial results	0.60
08/17/20	JD	Call with C. Robertson (Davis Polk) re: case progress.	0.20
08/18/20	HSB	Call with M. Huebner, E. Vonnegut, C. Robertson (all	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. DelConte, L. Donahue, H. Bhattal, G. Koch (all AlixPartners) re: weekly update and go forward planning call.	
08/18/20	HSB	Review Purdue's recent audited financial statements and related disclosures around intangible assets related to the Purdue tax discussion with Davis Polk.	0.50
08/18/20	JD	Review letter from the Debtors to the mediators re: go forward process.	0.30
08/19/20	JD	Distributable value call with H. Bhattal, J. DelConte (both AlixPartners), J. Turner, R. Schnitzler, T. Melvin (all PJT Partners), M. Atkinson (Province), K. Sheridan (Jefferies), L. Szlezinger (Jefferies).	0.30
08/19/20	HSB	Distributable value call with H. Bhattal, J. DelConte (both AlixPartners), J. Turner, R. Schnitzler, T. Melvin (all PJT Partners), M. Atkinson (Province), K. Sheridan (Jefferies), L. Szlezinger (Jefferies).	0.30
08/19/20	HSB	Compared UCC distributable value analysis to financial results and reviewed for reasonableness.	0.50
08/20/20	HSB	Review Adhansia information in preparation for related team discussion.	0.60
08/20/20	HSB	Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: case update and go forward planning.	1.20
08/20/20	JD	Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: case update and go forward planning.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
08/20/20	JD	Call with R. Aleali (Purdue) re: pos call follow ups.	0.20
08/20/20	NAS	Review press coverage related to Purdue settlement negotiations.	0.40
08/20/20	LJD	Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: case update and go forward planning.	1.20
08/21/20	SKL	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	NAS	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	SJC	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	JD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	JD	Prepare agenda for weekly team update call.	0.40
08/21/20	GJK	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	HSB	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	ADD	Prepare for AlixPartners Purdue engagement team update meeting.	0.50
08/21/20	ADD	Weekly team update call with H. Bhattal, S. Canniff, J.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	
08/25/20	HSB	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.90
08/25/20	GJK	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.90
08/25/20	JD	Prepare agenda for internal call with DPW, AlixPartners and PJT.	0.30
08/25/20	JD	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.90
08/25/20	JD	Review proposed revised fee order re: 2nd interim fee applications. Correspondence re: fee order and hearing with E. Kardos (AlixPartners).	0.30
08/25/20	LJD	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.90
08/26/20	JD	Prepare analysis of professional fee billings. Correspondence with E. Kardos (AlixPartners) re: same.	0.60
08/28/20	JD	Prepare agenda for AlixPartners weekly update call.	0.30
08/28/20	JD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/28/20	LJD	Weekly team update call with H. Bhattal, S. Canniff, J.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	
08/28/20	MFR	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/28/20	SKL	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/28/20	NAS	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/28/20	SJC	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/28/20	HSB	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/31/20	JD	Review and provide comments on current draft KEIP/KERP motion. Correspondence with Davis Polk re: same.	1.30
08/31/20	JD	Call with R. Aleali (Purdue) re: KEIP/KERP motion.	0.40
08/31/20	JD	Call with J. Lowne (Purdue) re: KEIP/KERP motion.	0.30
08/31/20	JD	Call with M. Huebner (Davis Polk) and M. Kesselman (Purdue) re: initial UCC feedback on KEIP/KERP motion.	0.30
Total			54.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	2.10	515.00	1,081.50
Sam K Lemack	2.10	515.00	1,081.50
Nate A Simon	2.50	515.00	1,287.50
Fernando O Silva	0.50	645.00	322.50
Sam J Canniff	2.10	645.00	1,354.50
HS Bhattal	10.30	840.00	8,652.00
Gabe J Koch	4.60	840.00	3,864.00
Mark F Rule	1.00	910.00	910.00
Jesse DelConte	21.70	950.00	20,615.00
Richard Collura	0.70	1,090.00	763.00
Lisa Donahue	6.90	1,195.00	8,245.50
Total Hours & Fees	54.50		48,177.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
08/01/20	JD	Correspondence with C. MacDonald (Purdue) re: professional fee payments.	0.20
08/03/20	SKL	Review latest feedback provided re: professional payment forecast and prepare updates to the latest cash forecast accordingly.	2.40
08/03/20	SKL	Review, reconcile and provide response to the latest Critical Vendor inquiry provided by R. Johansen (Purdue).	0.80
08/03/20	SKL	Review, reconcile and provide updated on latest prepetition invoice queries provided by C. MacDonald (Purdue).	1.10
08/03/20	SKL	Create accounts payable release files.	1.10
08/03/20	HSB	Review post-petition invoices submitted for payment.	0.20
08/03/20	JD	Review and provide comments on the latest cash forecast.	0.80
08/04/20	JD	Review updated cash forecast per management comments.	0.40
08/04/20	SKL	Create accounts payable release files.	0.90
08/04/20	SKL	Prepare updated US Trustee payment calculation and support and prepare update for J. Lowne (Purdue) accordingly.	0.90
08/04/20	SKL	Finalize review of final notes and feedback provided on the latest cash forecast and circulated for production.	0.70
08/04/20	SKL	Review final feedback provided internally re: cash forecast and circulate to the Purdue team for final sign-off.	1.70
08/05/20	SKL	Prepare updated Critical Vendor breakdown per C. Robertson (Davis Polk) request.	0.80
08/05/20	SKL	Finalize updates to the week ended 07/24 cash report and circulate internally for final sign-off.	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
08/05/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week ended 07/31 cash report.	2.10
08/05/20	SKL	Create accounts payable release files.	0.60
08/05/20	JD	Review and provide comments on latest cash forecast to actual analysis.	0.50
08/05/20	JD	Review material contract analysis from Davis Polk.	0.70
08/05/20	HSB	Review Cash Report (for week ended 07/24) prepared by S. Lemack (AlixPartners).	0.80
08/05/20	HSB	Review excel file with cash actuals tracking activity (for week ended 07/24) prepared by S. Lemack (AlixPartners).	0.90
08/06/20	HSB	Review supporting excel files for weekly cash report.	0.80
08/06/20	SKL	Review the latest Paysource transaction report and Integrated Payables report and categorized for the week ended 07/31 cash report.	2.20
08/06/20	SKL	Review and reconciled the latest investment activity re: East West cash transactions and updated the weekly cash report accordingly.	1.10
08/06/20	SKL	Review and reconcile the latest IAC cash activity and prepare updated list of open items for E. Nowakowski (Purdue) accordingly.	1.80
08/06/20	SKL	Review and reconcile the latest restructuring and retained professional payments against the latest fee application tracker.	1.10
08/06/20	SKL	Create accounts payable release files.	0.70
08/07/20	SKL	Create accounts payable release files.	0.70
08/07/20	SKL	Review and reconcile latest May-PEO Flash report and prepared non-PEO version.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
08/07/20	SKL	Update the Purdue cash forecast with the latest weekly cash actuals and prepared the updated forecast to actual slide of the weekly cash report accordingly.	1.10
08/07/20	SKL	Update the Rhodes cash forecast with the latest weekly cash actuals and prepared the updated forecast to actual slide of the weekly cash report accordingly.	1.30
08/07/20	SKL	Update the weekly cash report with the latest feedback provided by J. Liceaga (TXP) and E. Nowakowski (Purdue) and circulated internally for final sign-off.	1.80
08/07/20	HSB	Review list of outstanding government payments in response to query.	0.20
08/10/20	HSB	Review excel file with the PPLP Cash Flow Model	1.10
08/10/20	SKL	Review latest vendor match updates and update the vendor master accordingly.	2.30
08/10/20	SKL	Review the EastWest cash transactions from July and prepare updated cash activity report for the July MOR.	1.90
08/10/20	SKL	Finalize remaining updates to the 07/31 weekly cash report and circulate for approval.	0.70
08/10/20	SKL	Finalize updates to the non-PEO May Flash report and circulate for final approval.	1.20
08/10/20	SKL	Create accounts payable release files.	0.70
08/11/20	SKL	Create accounts payable release files.	0.60
08/11/20	SKL	Review and reconcile all July investment activity and prepare updated bank account balances for the July MOR.	1.90
08/11/20	SKL	Review and reconcile professional payments for July and prepare the updated professional payment piece of the July MOR and circulate to C. MacDonald (Purdue) for approval.	2.20
08/11/20	SKL	Review latest feedback provided re: customer deposits	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		and prepare updated list of open items and follow-up questions accordingly.	
08/11/20	SKL	Continue to review the May financial board deck and prepare the non-PEO Flash report accordingly.	2.10
08/11/20	SKL	Finalize updates to the non-PEO Flash report and circulate to J. Lowne (Purdue) and R. Aleali (Purdue) for final approval.	1.40
08/12/20	SKL	Prepare for and participate in discussion with C. MacDonald (Purdue) re: OCP firm payments and caps.	0.60
08/12/20	SKL	Reconcile latest OCP firm payments and prepare update for C. MacDonald (Purdue) and DPW team.	0.50
08/12/20	SKL	Create accounts payable release files.	0.90
08/12/20	SKL	Prepare final updates to the May non-PEO Flash report based on the latest feedback provided and circulated for final sign-off.	1.10
08/12/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week ended 08/07 cash report.	2.20
08/12/20	SKL	Review and reconcile the latest investment activity re: 08/07 cash report and update the IAC summary schedules accordingly.	1.30
08/12/20	SKL	Finalize updates to the professional payment piece of the July MOR based on the latest feedback provided by C. MacDonald (Purdue) and circulate accordingly.	1.90
08/12/20	HSB	Review revised version of the non-PEO Flash report for May 2020.	0.30
08/13/20	HSB	Review excel file with financial statements for June 2020, prepared by S. Lemack (AlixPartners).	0.80
08/13/20	HSB	Review Financial Statement (full deck) for June 2020.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
08/13/20	HSB	Review PEO Flash report for June 2020, prepared by S. Lemack (AlixPartners) and provided comments.	1.30
08/13/20	SKL	Review the latest Paysource transaction report and Integrated Payables report and categorized for the week ended 08/07 cash report.	2.20
08/13/20	SKL	Review and reconcile the latest restructuring and retained professional payments against the latest fee application tracker, and update the Restructuring fee schedule accordingly.	1.20
08/13/20	SKL	Review and reconcile the latest IAC cash activity and prepare updated list of open items for A. Green (Purdue) and T. Gabriele (Purdue) accordingly.	1.20
08/13/20	SKL	Create accounts payable release files.	0.30
08/13/20	SKL	Finalize updates to the Purdue cash summary and cash detail and compared forecast-to-actuals for the week ended 08/07.	2.10
08/13/20	SKL	Finalize updates to the Rhodes cash summary and cash detail and compared forecast-to-actuals for the week ended 08/07.	1.90
08/14/20	SKL	Create accounts payable release files.	0.70
08/14/20	SKL	Review and reconcile the Purdue weekly sales report provided by E. Nowakowski (Purdue) and formatted accordingly for production purposes.	0.90
08/14/20	SKL	Review and reconcile the Rhodes weekly sales report provided by P. Phouthasone (Purdue) and formatted accordingly for production purposes.	0.90
08/14/20	SKL	Began review of the June financial board deck and began preparing the June PEO Flash report accordingly.	2.30
08/14/20	SKL	Finalize updates to the June PEO Flash report based on the latest feedback provided and circulate to J. Lowne	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		(Purdue) and R. Aleali (Purdue) for final sign-off.	
08/14/20	SKL	Prepare final updates to the June PEO Flash report based on the feedback provided by J. Lowne (Purdue) and circulate for final approval.	0.80
08/14/20	HSB	Review weekly Cash Report prepared by S.Lemack (AlixPartners).	0.70
08/14/20	JD	Review and provide comments on this week's cash forecast to actual report.	0.50
08/17/20	SKL	Create accounts payable release files.	0.80
08/17/20	SKL	Review latest fee applications filed by Restructuring professionals and update the Restructuring professional fee tracker accordingly.	1.30
08/17/20	SKL	Review latest fee applications filed by Retained professionals and update the Retained professional fee tracker accordingly.	1.30
08/17/20	SKL	Review and reconcile the latest Prime Clerk claims report provided and updated the claims database accordingly re: newly filed claims.	2.30
08/18/20	SKL	Finalize remaining updates to the week ended 08/07 cash report and circulate to J. Lowne (Purdue) for final sign-off.	1.10
08/18/20	SKL	Create accounts payable release files.	0.70
08/18/20	SKL	Update the latest liquidation analysis with the June financials provided by E. Nowakowski (Purdue).	2.20
08/18/20	SKL	Continue to refresh the latest liquidation analysis with the June financials and prepare updates to the consolidated summary accordingly.	1.10
08/19/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		ended 08/14 cash report.	
08/19/20	SKL	Review the latest Paysource transaction report and Integrated Payables report and categorized for the week ended 08/14 cash report.	1.90
08/19/20	SKL	Review and reconcile latest IAC and investment transactions provided by J. Liceaga (TXP) and provided list of open items and question to E. Nowakowski (Purdue).	1.80
08/19/20	SKL	Review and reconcile latest indemnitee fee invoices provided by C. MacDonald (Purdue) and prepare accounts payable release files.	1.60
08/19/20	SKL	Review and reconcile the latest Rhodes critical vendor inquiry provided by R. Haberin (Purdue) and provide updated breakdown and analysis accordingly.	0.90
08/20/20	SKL	Finalize updates to the IAC cash summary based on the feedback provided by E. Nowakowski's (Purdue) team and updated the Purdue and Rhodes cash summaries accordingly.	1.70
08/20/20	SKL	Create accounts payable release files.	0.70
08/20/20	SKL	Review and reconcile latest rebate transactions and provide list of open items to C. Hobbick (Purdue) accordingly.	0.80
08/21/20	SKL	Finalize updates to the Purdue cash summary and cash detail and compared forecast-to-actuals for the week ended 08/14.	1.80
08/21/20	SKL	Finalize updates to the week ended 08/14 cash report and circulated for final sign-off.	1.80
08/21/20	SKL	Finalize updates to the Rhodes cash summary and cash detail and compared forecast-to-actuals for the week ended 08/14.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
08/21/20	JD	Review and provide comments on weekly cash forecast to actual report.	0.50
08/21/20	HSB	Review Weekly Cash Report for week ended 8/14 prepared by S. Lemack (AlixPartners).	0.60
08/24/20	SKL	Continued to review the latest claims register provided by Prime Clerk and update the claims database accordingly.	2.10
08/24/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week ended 08/21 cash report.	2.30
08/24/20	SKL	Create accounts payable release files.	0.60
08/25/20	SKL	Create accounts payable release files.	0.70
08/25/20	SKL	Review the latest Paysource transaction report and prepared open list of items for E. Nowakowski (Purdue) to review.	1.90
08/25/20	SKL	Review and reconcile the latest IAC and investment cash transactions and update the IAC summary and investment piece of the cash summary re: weekly cash report.	1.70
08/25/20	SKL	Review and reconcile the latest rebate payments and provide list of open items to C. Hobbick (Purdue) and P. Phouthasone (Purdue).	0.90
08/25/20	SKL	Continue to update the matching between the latest filed proof of claims and the scheduled liabilities.	1.40
08/25/20	SKL	Update the latest Purdue forecast with cash actuals and prepare the latest forecast-to-actuals analysis.	1.80
08/26/20	SKL	Update the latest Rhodes forecast with cash actuals and prepare the latest forecast-to-actuals analysis.	1.60
08/26/20	SKL	Review the latest professional payment info from July and prepare and distribute the OCP report to C. MacDonald	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		(Purdue) for review.	
08/26/20	SKL	Review and reconcile the latest debit balance inquiry provided by H. Benson (Purdue) and prepare updated analysis accordingly.	1.30
08/26/20	SKL	Review the latest information re: cash activity provided by R. Brown (Purdue) and update the week ended 08/21 cash report accordingly.	1.40
08/26/20	SKL	Create accounts payable release files.	0.70
08/27/20	SKL	Create accounts payable release files.	0.80
08/27/20	SKL	Finalize remaining updates to the IAC summary and update the cash summary accordingly.	0.90
08/27/20	SKL	Review and reconcile the latest feedback provided by C. MacDonald (Purdue) and finalized updates to the July OCP report.	2.60
08/27/20	SKL	Continue to review and reconcile the latest claims register provided by Prime Clerk and update the claims database accordingly.	2.40
08/27/20	SKL	Review the latest feedback provided by R. Brown (Purdue) and updated the weekly cash report accordingly.	0.90
08/28/20	SKL	Review the latest Purdue sales report provided by E. Nowakowski (Purdue) and prepare the Purdue sales by product report accordingly.	0.90
08/28/20	SKL	Review the latest Rhodes sales report provided by P. Phouthasone (Purdue) and prepare the Rhodes sales by product report accordingly.	0.80
08/28/20	SKL	Review and reconcile latest critical vendor inquiry provided and prepared updated analysis accordingly.	1.10
08/28/20	SKL	Finalize updates to the weekly cash report and circulate the updated deck for final sign-off.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
08/28/20	SKL	Review the latest fee applications filed on the docket and update the restructuring professional fee tracker accordingly.	1.80
08/28/20	SKL	Review the latest fee applications filed on the docket and update the retained professional fee tracker accordingly.	1.60
08/28/20	JD	Review and provide comments on weekly cash forecast to actual reporting.	0.40
08/28/20	HSB	Review Weekly Cash Report for week ended 8/21 prepared by S. Lemack (AlixPartners).	0.60
08/28/20	HSB	Review Weekly Sales Reports for Purdue & Rhodes prepared by S. Lemack (AlixPartners).	0.40
08/31/20	SKL	Finalize remaining updates to cash report and circulate to Davis Polk team for production.	0.40
08/31/20	SKL	Create accounts payable release files.	0.70
08/31/20	SKL	Finalize remaining updates to the latest OCP report and circulate to Davis Polk team.	1.00
08/31/20	SKL	Finalize remaining updates to the restructuring professional fee tracker and brought into the latest cash forecast accordingly.	1.40
08/31/20	SKL	Finalize remaining updates to the retained professional fee tracker and brought into the latest cash forecast accordingly.	1.20
08/31/20	SKL	Pull latest AP information from SAP and create and implement latest analysis into the Purdue and Rhodes cash forecasts accordingly.	1.40
08/31/20	SKL	Pull latest AR information from SAP and create and implement latest analysis into the Purdue and Rhodes cash forecasts accordingly.	1.20
08/31/20	SKL	Carry forward all cash summaries on the latest 13-week	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		cash forecast and begin updating the forecast accordingly.	
Total			<u><u>157.50</u></u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Cash Management
Client/Matter # 012589.00103

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	143.40	515.00	73,851.00
HS Bhattal	10.10	840.00	8,484.00
Jesse DelConte	4.00	950.00	3,800.00
Total Hours & Fees	157.50		86,135.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
08/03/20	JD	Call with J. Feltman, R. Levy, M. Vitti (all Duff & Phelps), J. Turner, R. Schnitzler, T. Melvin (all PJT), W. Curran (Davis Polk) re: organization structure diligence update.	1.10
08/03/20	MBB	Review claims detail to determine duplicate claims.	2.90
08/03/20	MBB	Review claims detail and assigned match numbers	1.90
08/03/20	JD	Review UCC diligence requests re: professional fee payments.	0.30
08/04/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), C. Oluwole (Davis Polk) and T. Melvin (PJT) re: UCC professional fee diligence requests.	0.50
08/04/20	JD	Call with M. Atkinson (Province) and J. Turner (PJT) re: adcom.	0.40
08/04/20	JD	Call with J. Turner (PJT) re: next steps on adcom diligence.	0.20
08/04/20	JD	Correspondence with FTI re: diligence questions on Adhansia.	0.40
08/04/20	JD	Review responses to various FTI diligence requests.	0.50
08/04/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), C. Oluwole (Davis Polk) and T. Melvin (PJT) re: UCC professional fee diligence requests.	0.50
08/05/20	JD	Review second diligence list re: Project Catalyst.	0.30
08/06/20	JD	Review materials created by PJT in response to request from Shareholders for business plan bridges.	0.30
08/06/20	JD	Call with M. Huebner, E. Vonnegut, B. Kaminetsky (all Davis Polk) re: UCC pre-call.	0.30
08/06/20	JD	Call with M. Huebner, E. Vonnegut, B. Kaminetzky (all Davis Polk), A. Preis, M. Hurley (both Akin Gump), M. Atkinson (Province) re: claims process.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
08/06/20	ADD	Research and locate contracts / agreement for a counter party at the request of Davis Polk.	0.80
08/07/20	MBB	Review claims detail to determine duplicate claims.	2.80
08/09/20	ADD	Upload UCC diligence production provided by Davis Polk eDiscovery team for upload to the data room.	1.50
08/09/20	ADD	Prepare UCC diligence production provided by Davis Polk eDiscovery team for upload to the data room.	2.70
08/09/20	JD	Call with M. Atkinson (Province) re: suboxone.	0.30
08/10/20	JD	Review correspondence and input from Purdue and Dechert re: FTI insurance questions.	0.30
08/10/20	JD	Review data room for historical sales details per FTI diligence request.	0.70
08/10/20	JD	Review and provide comments on draft email to Mundipharma re: open diligence requests. Correspondence re: same.	0.30
08/10/20	JD	Call with M. Diaz, B. Bromberg (both FTI) and T. Melvin (PJT) re: future insurance costs.	0.50
08/10/20	ADD	Review and compile documentation submitted in response to diligence requests in preparation for upload to the data room.	2.20
08/10/20	ADD	Review and research diligence questions submitted by the FTI, compiling necessary information.	1.60
08/10/20	ADD	Research insurance file production history at the request of Davis Polk.	1.30
08/11/20	ADD	Research Purdue purchase orders issued under RT agreements and identify potential data elements in SAP to complete the analysis.	2.60
08/11/20	ADD	Research diligence questions submitted by the FTI, compiling necessary information.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
08/11/20	JD	Call with M. Atkinson (Province), A. Preis, S. Brauner (both Akin Gump), J. Turner (PJT), P. Strassburger, R. Silbert (both Purdue) and P. Mathers (Kleinfeld) re: AdCom meeting.	0.70
08/12/20	ADD	Review outstanding UCC diligence requests and follow up with outstanding item.	2.20
08/12/20	ADD	Upload approved materials to the data room and update permissions.	1.50
08/13/20	JD	Review various IAC agreements to be shared with creditor advisors.	0.30
08/13/20	MBB	Review claims detail to determine duplicate claims.	2.40
08/14/20	JD	Call with M. Diaz, B. Bromberg (FTI), S. Birnbaum (Dechert), A. Kramer (Reed Smith), C. Ricarte, R. Aleali (Purdue), T. Melvin (PJT) re: Insurance Proceeds.	0.40
08/14/20	JD	Review IAC licensing agreements currently uploaded to the data room per an AHC request.	0.50
08/17/20	JD	Review and comment on draft responses to AHC OxyContin diligence questions.	0.40
08/17/20	ADD	Compile and transfer files provided in response to diligence requests in preparation for review, processing and production to the creditor committees.	1.90
08/18/20	ADD	Research employment history to document debtor employment at the request of Davis Polk.	0.50
08/18/20	ADD	Update insider titles employment diligence request and submit for approval and production in response to creditor diligence request.	1.40
08/18/20	JD	Review updated responses with management revisions to AHC OxyContin diligence questions.	0.30
08/18/20	JD	Review and provide comments on latest draft email to	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		Mundipharma for diligence. Review latest iterations.	
08/18/20	JD	Correspondence with Province and PJT re: distributable value.	0.20
08/18/20	JD	Correspondence with Province re: Collegium conversations.	0.20
08/18/20	JD	Call with M. Atkinson (Province) re: UCC AdCom discussion follow up.	0.20
08/19/20	JD	Call with M. Atkinson (Province) re: PBGC.	0.20
08/19/20	JD	Call with E. Suric, M. Diaz, B. Bromberg (all FTI), M. Atkinson (Province), L. Sczlezinger, K. Sheridan (both Jefferies), J. Turner, T. Melvin, G. Sim (all PJT), A. DePalma, J. DelConte (both AlixPartners), J. Lowne, M. Ronning, D. Rosen, K. Gadski (all Purdue) re: OxyContin scenarios.	1.00
08/19/20	ADD	Prepare production of diligence materials provide by Davis Polk's eDiscovery team for upload to the data room	2.30
08/19/20	ADD	Upload files to upload to the data room and provide access to the creditor committees.	1.80
08/19/20	ADD	Call with E. Suric, M. Diaz, B. Bromberg (all FTI), M. Atkinson (Province), L. Sczlezinger, K. Sheridan (both Jefferies), J. Turner, T. Melvin, G. Sim (all PJT), A. DePalma, J. DelConte (both AlixPartners), J. Lowne, M. Ronning, D. Rosen, K. Gadski (all Purdue) re: OxyContin scenarios.	1.00
08/19/20	HSB	Review letter from UCC to Mediation parties.	0.40
08/19/20	HSB	Review net distributable value analysis from UCC to mediation parties.	0.40
08/20/20	JD	Review latest draft Mundipharma email per comments from AHC.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
08/23/20	JD	Correspondence with Province and management re: E&Y scope expansion.	0.30
08/23/20	ADD	Prepare and upload materials requested by the creditor committees and processed by the Davis Polk eDiscovery team to the data room.	1.50
08/27/20	ADD	Prepare UCC and Consenting/Non-consenting states productions for upload to the data room and upload files to data room.	1.10
08/28/20	ADD	Compile items in response to creditor diligence requests for approval and production to the data room.	1.20
08/30/20	ADD	Prepare UCC and Consenting/Non-consenting states productions for upload to the data room and upload files to data room.	3.20
08/31/20	ADD	Prepare UCC and Consenting/Non-consenting states productions for upload to the data room and upload files to data room.	2.20
08/31/20	JD	Call with M. Atkinson (Province) re: initial feedback on KEIP/KERP motion.	0.20
Total			61.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Fee Recap:

Consultant	Hours	Rate	Amount
Mary B Betik	10.00	315.00	3,150.00
Andrew D DePalma	37.40	515.00	19,261.00
HS Bhattal	0.80	840.00	672.00
Jesse DelConte	12.80	950.00	12,160.00
Total Hours & Fees	61.00		35,243.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
08/04/20	JD	Review US Trustee payment schedule against MORs filed to date.	0.30
08/10/20	JD	Correspondence with the US Trustee's Office, Davis Polk and S. Lemack (AlixPartners) re: latest quarterly fee payment.	0.30
08/12/20	NAS	Request data sources for insider payments section of July MOR and analyze data received.	1.40
08/13/20	NAS	Review and analyze data provided for insider payments section of July 2020 MOR.	0.80
08/14/20	NAS	Analyze data for insider payments section of July 2020 MOR.	0.50
08/17/20	NAS	Finalize insider payments section of July MOR and review for accuracy.	1.50
08/20/20	JD	Review and provide comments on July MOR prior to finalizing and filing.	0.40
Total			<u><u>5.20</u></u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Fee Recap:

Consultant	Hours	Rate	Amount
Nate A Simon	4.20	515.00	2,163.00
Jesse DelConte	1.00	950.00	950.00
Total Hours & Fees	5.20		3,113.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/03/20	JD	Review and mark-up distributable value presentation so that it can be shared with market participants from the UCC.	1.20
08/03/20	JD	Call with P. Strassburger (Purdue) re: upcoming advisory committee meeting.	0.30
08/03/20	JD	Call with E. Vonnegut (Davis Polk) re: claims process.	0.20
08/03/20	JD	Call with J. Turner, J. Arsic (both PJT), G. Koch, N. Simon, J. DelConte (all AlixPartners), C. Robertson, C. Oluwole, A. Lutchen (Davis Polk) re: Mundipharma diligence update.	0.60
08/03/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: current Mundipharma diligence priorities.	0.30
08/03/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to determine necessary updates within first four sections of Mundipharma diligence report.	2.10
08/03/20	GJK	Call with J. Turner, J. Arsic (both PJT), G. Koch, N. Simon, J. DelConte (all AlixPartners), C. Robertson, C. Oluwole, A. Lutchen (Davis Polk) re: Mundipharma diligence update.	0.60
08/03/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review takeaways from discussion with PJT and DPW and discuss implications for Mundipharma diligence process.	0.40
08/03/20	GJK	Coordinate and follow up on Mundipharma diligence.	1.50
08/03/20	GJK	Prepare for walkthrough of Mundipharma report and adjustments, including outlining outstanding information needs.	1.50
08/03/20	GJK	Prep for PJT, DPW call.	0.30
08/03/20	GJK	Review Mundipharma report re: potential walkthrough of process with other advisors.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/03/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: current Mundipharma diligence priorities.	0.30
08/03/20	NAS	Review notes and follow up items from prior discussions with other Mundipharma diligence advisors.	0.60
08/03/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to determine necessary updates within first four sections of Mundipharma diligence report.	2.10
08/03/20	NAS	Call with J. Turner, J. Arsic (both PJT), G. Koch, N. Simon, J. DelConte (all AlixPartners), C. Robertson, C. Oluwole, A. Lutchen (Davis Polk) re: Mundipharma diligence update.	0.60
08/03/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review takeaways from discussion with PJT and DPW and discuss implications for Mundipharma diligence process.	0.40
08/03/20	NAS	Review raw data provided by Mundipharma to ensure that all product/market pairs have cost information.	1.50
08/03/20	LJD	Review staffing and work on transition plan	0.70
08/03/20	LJD	Call with M. Kesselman (Purdue) re: case status update.	0.30
08/03/20	LJD	Call with K. Buckfire - board member RE: update on case progress.	0.50
08/03/20	JD	Update and check latest attrition data.	0.50
08/03/20	JD	Review weekly IMS data prior to posting.	0.40
08/03/20	JD	Review opioid sensitivity case back up data. Review commentary from PJT re: same.	0.60
08/03/20	JD	Review final files that are responsive to UCC opioid case diligence questions.	0.70
08/03/20	KM	Create and populate site visit folder re: virtual site visits.	0.90
08/03/20	KM	Coordinate retained liabilities analysis re: diligence request.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/03/20	KM	Edit and augment Building 5 and 7 site visit materials re: project Catalyst.	1.70
08/03/20	KM	Call with A. Nadeau (Purdue) re: project Catalyst virtual tour of warehousing and upper mill.	1.00
08/03/20	KM	Analysis and presentation creation re: Upper Mill site tour for project Catalyst.	0.80
08/03/20	KM	Meeting with J. Doyle, K. McCarthy (both Purdue), M. Gibson (Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst assigned contracts plan.	0.70
08/03/20	JD	Correspondence with management re: professional fee payments.	0.30
08/03/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: contract review and process.	0.10
08/03/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.50
08/03/20	KM	Analysis re: project Catalyst supply contracts.	0.50
08/03/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.50
08/03/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: contract review and process.	0.10
08/03/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.90
08/03/20	KM	Coordinate VDR updates with Rhodes Operations and Finance re: project Catalyst.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/03/20	KM	Prepare presentation documents re: virtual site visit for project Catalyst.	2.40
08/03/20	ADD	Meeting with J. Doyle, K. McCarthy (both Purdue), M. Gibson (Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst assigned contracts plan.	0.70
08/04/20	ADD	Meeting with J. Doyle, K. McCarthy (both Purdue), M. Gibson (Skadden) and A. DePalma, K. McCarthy (both AlixPartners) re: project Catalyst assigned contracts plan.	0.80
08/04/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCarthy (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/04/20	ADD	Meeting with D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (both PJT), A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst VDR.	0.50
08/04/20	KM	Meeting with D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (both PJT), A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst VDR.	0.50
08/04/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCarthy (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/04/20	KM	Coordinate site visits re: project Catalyst.	0.10
08/04/20	KM	Meeting with J. Doyle, K. McCarthy (both Purdue), M. Gibson (Skadden) and A. DePalma, K. McCarthy (both AlixPartners) re: project Catalyst assigned contracts plan.	0.80
08/04/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/04/20	KM	Create Grounds overview presentation re: virtual site visit.	0.80
08/04/20	KM	Review, edit and upload VDR documents re: project Catalyst.	0.40
08/04/20	KM	Analysis re: payroll, benefits and taxes in support of Catalyst.	0.60
08/04/20	KM	Call with R. Schnitzler (PJT) re: diligence process and management.	0.20
08/04/20	KM	Create virtual site visit tour materials re: RTC and grounds and Building 9.	1.10
08/04/20	KM	Create virtual site visit tour materials re: RTC and grounds.	2.20
08/04/20	KM	Review and analysis re: supply agreement diligence for Catalyst.	1.10
08/04/20	KM	Analysis re: supply agreements for diligence.	1.10
08/04/20	JD	Review presentation presented to the shareholders in order to prepare a bridge to the latest business plan.	1.20
08/04/20	JD	Call with P. Strassburger, R. Fanelli (both Purdue) and P. Mathers (Kleinfield Kaplan) re: adcom.	0.50
08/04/20	JD	Correspondence with M. Kesselman (Purdue) re: responses to UCC questions on the AdCom.	0.60
08/04/20	JD	Review updated bridges for the various OxyContin scenarios.	0.70
08/04/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: post weekly professionals call planning.	0.50
08/04/20	GJK	Review documents and outstanding country level items and Canada projections and outstanding questions.	2.30
08/04/20	GJK	Analyze working capital and excess cash needs at Mundipharma.	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/04/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review necessary revisions to prior draft of Mundipharma diligence report.	1.60
08/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review necessary revisions to prior draft of Mundipharma diligence report.	1.60
08/04/20	NAS	Analyze product/market-level variances between latest Mundipharma sales forecast and prior price/volume data.	2.10
08/05/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) re: latest developments in Purdue case and current status of Mundipharma diligence.	0.90
08/05/20	NAS	Review press coverage about new reported DOJ Purdue charges.	0.50
08/05/20	NAS	Finalize revised sales forecast vs. price/volume comparison and provide summary to G. Koch (AlixPartners).	0.80
08/05/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) re: latest developments in Purdue case and current status of Mundipharma diligence.	0.90
08/05/20	GJK	Follow up planning on diligence based on Norton Rose discussion.	0.80
08/05/20	GJK	Analyze major movements in cost structure between COGS and review previous Tech Ops presentation and VDD comments.	2.50
08/05/20	GJK	Catch up call with J. DelConte and G. Koch (both AlixPartners) re: Mundipharma diligence.	0.20
08/05/20	GJK	Call with I. McClatchey (Norton Rose) re: Mundipharma diligence.	1.10
08/05/20	GJK	Identify potential cost reduction impact areas from reducing footprint.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/05/20	JD	Catch up call with R. Aleali (Purdue) re: open diligence items.	0.30
08/05/20	JD	Catch up call with J. DelConte and G. Koch (both AlixPartners) re: Mundipharma diligence.	0.20
08/05/20	JD	Call with K. McCarthy, B. Miller (both Purdue), A. Lele, W. Taylor, E. Diggs, C. Robertson (all Davis Polk), J. DelConte and A. DePalma (both AlixPartners) re: material contracts.	0.60
08/05/20	JD	Meeting with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: cure costs.	0.50
08/05/20	JD	Review materials to produce to the UCC re: AdCom. Correspondence with Davis Polk re: same.	0.80
08/05/20	JD	Draft biweekly agenda for the professionals call tomorrow.	0.40
08/05/20	JD	Review list of critical vendors per request from Davis Polk.	0.50
08/05/20	JD	Review Project Catalyst diligence request questions.	0.40
08/05/20	JD	Review list of material contracts to provide to Davis Polk.	1.50
08/05/20	JD	Review final details re: UCC insurance diligence response.	0.30
08/05/20	KM	Analysis re: projected inventory coverage for Catalyst.	0.60
08/05/20	KM	Meeting with D. Lundie, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: review of project Catalyst bidders questions.	1.00
08/05/20	KM	Analysis and editing re: virtual site tour for project Catalyst.	1.50
08/05/20	KM	Review, edit and upload VDR documents re: project Catalyst.	1.00
08/05/20	KM	Call with D. Fogel (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: compensation, payroll and benefits	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: project Catalyst.	
08/05/20	ADD	Meeting with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: cure costs.	0.50
08/05/20	ADD	Call with K. McCarthy, B. Miller (both Purdue), A. Lele, W. Taylor, E. Diggs, C. Robertson (all Davis Polk), J. DelConte and A. DePalma (both AlixPartners) re: material contracts.	0.60
08/05/20	KM	Virtual site visit document editing re: project Catalyst.	1.20
08/05/20	KM	Call with J. Doyle, K. McCarthy (both Purdue), M. Gibson, A. Gallogly (both Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: assigned contracts workplan and activities.	1.00
08/05/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
08/05/20	KM	Meeting with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: cure costs.	0.50
08/05/20	KM	Call with D. Lundie (Purdue) re: project Catalyst.	0.30
08/05/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.70
08/05/20	KM	Coordinate supply agreement review re: diligence in support of project Catalyst.	0.60
08/05/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
08/05/20	ADD	Call with J. Doyle, K. McCarthy (both Purdue), M. Gibson, A. Gallogly (both Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: assigned contracts workplan and	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		activities.	
08/05/20	ADD	Call with D. Fogel (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: compensation, payroll and benefits re: project Catalyst.	0.60
08/05/20	ADD	Research Purdue client repositories and prior efforts to compile material contracts.	1.40
08/06/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (AlixPartners) re: virtual site visit practice and tech check.	0.60
08/06/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: cure costs for term sheets.	0.50
08/06/20	ADD	Meeting with R. Shamblen, A. Soma, R. Deady, A. Nadeau (all Purdue), K. McCafferty, A. DePalma (both AlixPartners), Ramboll diligence team re: Catalyst Phase I site interview.	2.50
08/06/20	ADD	Call with J. Doyle, K. McCarthy (both Purdue), M. Gibson, A. Gallogly (both Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: assigned contracts workplan and activities.	0.80
08/06/20	ADD	Call with W. DiNicola (Purdue), A. DePalma, K. McCafferty (AlixPartners) re: payroll-benefits-pension-taxes diligence inquiry.	0.50
08/06/20	KM	Review, edit and upload VDR documents re: project Catalyst.	0.30
08/06/20	KM	Communication with third party re: virtual site tour.	0.30
08/06/20	KM	Call with W. DiNicola (Purdue), A. DePalma, K. McCafferty (AlixPartners) re: payroll-benefits-pension-taxes diligence inquiry.	0.50
08/06/20	KM	Prepare support materials re: molecules of interest on	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		virtual visit.	
08/06/20	KM	Call with J. Doyle, K. McCarthy (both Purdue), M. Gibson, A. Gallogly (both Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: assigned contracts workplan and activities.	0.80
08/06/20	KM	Call with K. McCafferty, J. DelConte (both AlixPartners), R. Schnitzler, J. Wang (both PJT), M. Gibson, R. Schlossberg, A. Gallogly (all Skadden), D. Lundie, K. McCarthy (both Purdue) re: Project Catalyst.	0.70
08/06/20	KM	Call with R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden), Noramco diligence team re: project Catalyst transaction documents.	0.80
08/06/20	KM	Meeting with D. Lundie, D. Fogel, K. McCarthy (all Purdue), R. Schnitzler (PJT), third party diligence team re: business diligence inquiries.	0.50
08/06/20	KM	Meeting with D. Lundie, D. Fogel, K. McCarthy (all Purdue), R. Schnitzler (PJT) re: preparation for third party business diligence call.	0.50
08/06/20	KM	Meeting with R. Shamblen, A. Soma, R. Deady, A. Nadeau (all Purdue), K. McCafferty, A. DePalma (both AlixPartners), Ramboll diligence team re: Catalyst Phase I site interview.	2.50
08/06/20	KM	Prepare presentation re: Phase I diligence meeting.	0.40
08/06/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: cure costs for term sheets.	0.50
08/06/20	KM	Update documents re: virtual site visit for Catalyst.	0.30
08/06/20	JD	Correspondence with M. Kesselman (Purdue) and M. Huebner (Davis Polk) re: questions from the UCC on Suboxone.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/06/20	JD	Call with K. McCafferty, J. DelConte (both AlixPartners), R. Schnitzler, J. Wang (both PJT), M. Gibson, R. Schlossberg, A. Gallogly (all Skadden), D. Lundie, K. McCarthy (both Purdue) re: Project Catalyst.	0.70
08/06/20	JD	Call with P. Strassburger, R. Fanelli (both Purdue) and P. Mathers (Kleinfeld) re: AdCom presentation.	0.50
08/06/20	JD	Review and provide comments on latest draft KEIP/KERP motion.	1.20
08/06/20	JD	Review latest draft KEIP/KERP LTRP analysis. Update analysis from last year for 2021 and 2022.	2.70
08/06/20	JD	Finalize initial list of material contracts to provide to Davis Polk to review.	0.80
08/06/20	JD	Review updated materials from the company re: AdCom.	0.50
08/06/20	JD	Review AdCom executive summary to potentially share with the UCC.	0.40
08/06/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (AlixPartners) re: virtual site visit practice and tech check.	0.60
08/06/20	KM	Analysis and editing re: virtual site tour for project Catalyst.	0.80
08/06/20	KM	Call with R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden), Mallinckrodt diligence team re: project Catalyst transaction documents.	0.50
08/06/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.90
08/06/20	KM	Analysis re: cure costs for project Catalyst.	0.40
08/06/20	GJK	Outline revisions to Mundipharma report potential risk	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		adjustments.	
08/06/20	GJK	Outline new sections for updated Mundipharma report.	2.00
08/06/20	GJK	Review Mundipharma PV data variance analysis.	0.50
08/06/20	GJK	Draft updates to Key Finding slides for Mundipharma report based on CEO transformation initiatives.	2.00
08/06/20	LJD	Prepare for and attend coordination call with Prime Clerk	0.30
08/06/20	LJD	Prepare for and attend call with team re: claims reconciliation process and staffing	0.20
08/06/20	IA	Call with J. Tran (Avrio) re: process for updating monthly dashboard and pushing through July results.	1.20
08/07/20	GJK	Assess data source files in preparation for call with G. Koch, N. Simon (both AlixPartners).	0.60
08/07/20	GJK	Plan and coordinate for follow up with other financial advisors re: Mundipharma next steps and information needs.	2.30
08/07/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) re: data source completeness testing, price/volume vs. revised forecast, and priorities moving forward.	1.10
08/07/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) re: data source completeness testing, price/volume vs. revised forecast, and priorities moving forward.	1.10
08/07/20	NAS	Analyze source data variances for product/market pairs in price/volume and revised forecast files.	0.70
08/07/20	NAS	Compare product/market benchmarking data across first and second iteration of Mundipharma business plan model.	0.80
08/07/20	NAS	Correspondence with Province and FTI re: Mundipharma diligence process.	0.20
08/07/20	NAS	Compare cost structure in first and second iteration of	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma business plan models.	
08/07/20	NAS	Test Mundipharma business plan source data to ensure completeness.	1.50
08/07/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson (Skadden), K. McCafferty, A. DePalma (both AlixPartners) re: project Catalyst APA schedules.	0.80
08/07/20	KM	Call with J. Lieberman (SK Capital), R. Schnitzler (PJT), A. DePalma, K. McCafferty (both AlixPartners) re: diligence follow up.	0.50
08/07/20	KM	Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), A. DePalma, K. McCafferty, J. DelConte (all AlixPartners), Bidder diligence team re: Rhodes Technologies plant tour part 2.	1.50
08/07/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue) re: virtual site visit afternoon session prep.	0.50
08/07/20	KM	Call with D. Lundie (Purdue) re: approach for virtual site visit.	0.20
08/07/20	KM	Document edits and corrections re: project Catalyst virtual site visit.	0.40
08/07/20	KM	Analysis re: materials agreements for project Catalyst.	0.70
08/07/20	JD	Call with E. Vonnegut, D. Consla, S. Brecher (Davis Polk), S. Hinden, D. Sims, J. Gartrell (all Wilis Towers Watson) re: KEIP/KERP.	0.90
08/07/20	JD	Review estimates for month end professional accruals.	0.40
08/07/20	JD	Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), K. McCafferty, A. DePalma, J. DelConte (all AlixPartners), bidder diligence team re: Rhodes	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/07/20	JD	Technologies plant tour part 1. Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), A. DePalma, K. McCafferty, J. DelConte (all AlixPartners), Bidder diligence team re: Rhodes Technologies plant tour part 2.	1.50
08/07/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	1.30
08/07/20	KM	Call with R. Shamblen (Purdue) re: project Catalyst site visit debrief.	0.10
08/07/20	KM	Continue virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	0.30
08/07/20	KM	Meeting with K. McCarthy (Purdue), PJT, M. Gibson (Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	1.20
08/07/20	KM	Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), K. McCafferty, A. DePalma, J. DelConte (all AlixPartners), bidder diligence team re: Rhodes Technologies plant tour part 1.	2.40
08/07/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.50
08/07/20	KM	Edits and final document preparation re: Catalyst virtual site visit.	0.90
08/07/20	ADD	Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), K. McCafferty, A. DePalma, J. DelConte	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(all AlixPartners), bidder diligence team re: Rhodes Technologies plant tour part 1.	
08/07/20	ADD	Meeting with K. McCarthy (Purdue), PJT, M. Gibson (Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	1.20
08/07/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	1.30
08/07/20	ADD	Continue virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	0.30
08/07/20	ADD	Call with J. Lieberman (SK Capital), R. Schnitzler (PJT), A. DePalma, K. McCafferty (both AlixPartners) re: diligence follow up.	0.50
08/07/20	ADD	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson (Skadden), K. McCafferty, A. DePalma (both AlixPartners) re: project Catalyst APA schedules.	0.80
08/07/20	ADD	Update July liability subject to compromise calculation for Purdue accounting team used for monthly financial statement close process.	2.80
08/07/20	ADD	Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), A. DePalma, K. McCafferty, J. DelConte (all AlixPartners), Bidder diligence team re: Rhodes Technologies plant tour part 2.	1.50
08/09/20	JD	Correspondence with M. Huebner, C. Robertson (Davis Polk) and J. Turner (PJT) re: conversation with Province.	0.30
08/09/20	JD	Correspondence with M. Huebner, J. McClammy, C. Robertson (all Davis Polk) and P. Strassburger, R. Fanelli, R. Silbert, M. Kesselman (all Purdue) re: committee	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		suboxone response.	
08/09/20	KM	Analysis re: compensation benefits details for project Catalyst.	2.50
08/10/20	KM	Upload and review re: schedules and exhibits for project Catalyst.	0.10
08/10/20	KM	Analysis re: R&D portfolio for project Catalyst diligence.	0.80
08/10/20	KM	Review, edit and upload VDR documents re: project Catalyst.	2.20
08/10/20	KM	Call with R. Schnitzler (PJT), Noramco diligence team re: project Catalyst diligence and submission timing.	0.70
08/10/20	KM	Benefits analysis re: project Catalyst.	1.20
08/10/20	KM	Analysis and tracking re: open diligence requests.	1.70
08/10/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.60
08/10/20	KM	Analysis re: employee compensation.	0.30
08/10/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst offer process.	0.20
08/10/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst APA schedules.	0.60
08/10/20	KM	Review APA disclosure schedules re: project Catalyst.	0.80
08/10/20	JD	Review weekly IMS details to provide to creditor advisors.	0.30
08/10/20	JD	Call with J. Turner (PJT), C. Robertson and M. Huebner (Davis Polk) re: UCC Suboxone discussions.	0.30
08/10/20	JD	Call with J. Lowne (Purdue) re: suboxone discussions with UCC and next steps.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/10/20	JD	Call with P. Strassburger, R. Silbert (Purdue), C. Robertson (Davis Polk) and P. Mathers (Kleinfeld) re: UCC AdCom discussion.	0.50
08/10/20	JD	Correspondence with D. Fogel (Purdue) re: Suboxone historical and financial details.	0.40
08/10/20	JD	Edit memo on Suboxone historical and forecast financial details.	0.60
08/10/20	JD	Review latest UCC AdCom materials. Edit and prepare for production.	0.70
08/10/20	JD	Review materials collected re: insurance costs in the forecast in advance of the call with FTI.	0.60
08/10/20	JD	Review May non-PEO monthly flash report to provide to creditors.	0.70
08/10/20	JD	Review updated AdCom slides from R. Silbert (Purdue) for UCC call.	0.30
08/10/20	JD	Review diligence questions from FTI re: OxyContin only scenario.	0.40
08/10/20	JD	Review draft responses to FTI diligence questions re: OxyContin only scenarios.	0.50
08/10/20	ADD	Review and compile material contracts and submit contracts to Purdue for review.	2.30
08/10/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.60
08/10/20	NAS	Review new diligence files uploaded to Purdue data room.	0.50
08/10/20	NAS	Call with Province, FTI professionals and G. Koch, N. Simon (both AlixPartners) re: outstanding Mundipharma diligence items.	0.50
08/10/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) to	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		prepare for and discuss call with Province and FTI professionals.	
08/10/20	NAS	Build comparison of product/market-level cost structure in first and second iterations of Mundipharma management forecast.	3.50
08/10/20	NAS	Review Mundipharma diligence request letter drafted by G. Koch (AlixPartners) and provide comments.	0.60
08/10/20	NAS	Prepare for Mundi diligence process strategy call with FTI and Province.	0.30
08/10/20	GJK	Update analysis framework for Malta model review.	2.00
08/10/20	GJK	Correspondence with J. DelConte (AlixPartners) re: Mundipharma diligence.	0.20
08/10/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) to prepare for and discuss call with Province and FTI professionals.	0.50
08/10/20	GJK	Call with Province, FTI professionals and G. Koch, N. Simon (both AlixPartners) re: outstanding Mundipharma diligence items.	0.50
08/10/20	GJK	Draft Mundipharma email and notes from Province and FTI.	2.50
08/10/20	GJK	Plan and coordinate Mundipharma diligence.	1.50
08/11/20	GJK	Assess diligence information provided for support for Mundipharma projected cost improvements.	2.50
08/11/20	GJK	Review open LAM Region items and available diligence information (including VDD).	2.40
08/11/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) to walk through changes in product/market pair cost structures between versions of Mundipharma management's forecasts.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/11/20	NAS	Finalize comparison of product/market pair cost structures between iterations of Mundipharma management forecast.	1.60
08/11/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) to walk through changes in product/market pair cost structures between versions of Mundipharma management's forecasts.	1.00
08/11/20	LJD	Review and comment on OTC combination analysis	0.80
08/11/20	ADD	Call with E. Diggs, D. Lojac, W. Taylor, J. Schwartz (all Davis Polk), R. Aleali, K. McCarthy, B. Miller (Purdue), J. Bragg, M. Florence (both Skadden), T. Melvin (PJT), J. DelConte and A. DePalma (both AlixPartners) re: Trust Transfer process.	0.70
08/11/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.50
08/11/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang (both PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.50
08/11/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: diligence tracking and VDR updates.	0.50
08/11/20	ADD	Compile system access instructions for new users and provided information to Davis Polk team members.	1.20
08/11/20	JD	Call with E. Diggs, D. Lojac, W. Taylor, J. Schwartz (all Davis Polk), R. Aleali, K. McCarthy, B. Miller (Purdue), J. Bragg, M. Florence (both Skadden), T. Melvin (PJT), J. DelConte and A. DePalma (both AlixPartners) re: Trust Transfer process.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/11/20	JD	Correspondence with M. Ronning and B. Shank (both Purdue) re: managed care updates.	0.30
08/11/20	JD	Review materials and prepare for AdCom meeting.	0.40
08/11/20	JD	Correspondence with PJT and Davis Polk re: Suboxone next steps.	0.50
08/11/20	JD	Correspondence with D. Fogel (Purdue) and update memo on historical and forecasted Suboxone financials.	0.30
08/11/20	JD	Review request from the Ad Hoc Committee to share various PEO materials with their committee members.	0.80
08/11/20	KM	Analysis re: inventory scenarios for project Catalyst.	1.80
08/11/20	KM	Review and document management re: benefits diligence for project Catalyst.	1.60
08/11/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: diligence tracking and VDR updates.	0.50
08/11/20	KM	Analysis re: transition services for project Catalyst.	0.30
08/11/20	KM	Meeting with D. Fogel, W. DiNicola, J. Lowne (all Purdue), R. Schnitzler (PJT) re: transitions services analysis for Catalyst.	0.80
08/11/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang (both PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.50
08/11/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.50
08/11/20	KM	Analysis and documentation re: R&D portfolio for project Catalyst diligence.	0.40
08/11/20	KM	Analysis and update diligence tracker and open items re:	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		project Catalyst.	
08/12/20	KM	Diligence updates to VDR re: project Catalyst.	1.30
08/12/20	KM	Analysis and coordination re: benefits policies for VDR.	1.50
08/12/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Review approved documents and upload materials to Project Catalyst VDR	1.20
08/12/20	KM	Coordination of diligence tracking re: project Catalyst.	0.30
08/12/20	KM	Call with D. Fogel (Purdue) re: project Catalyst.	0.30
08/12/20	KM	Detailed compensation analysis re: project Catalyst VDR.	1.60
08/12/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/12/20	KM	Analysis and document management re: environmental due diligence.	1.30
08/12/20	JD	Review and provide comments on PJT OTC analysis.	1.20
08/12/20	JD	Review updated PJT materials pulled together in response to open shareholder diligence requests.	0.70
08/12/20	JD	Call with J. Lowne (Purdue) re: business plan refresh.	0.20
08/12/20	JD	Call with R. Aleali (Purdue) re: open diligence items and trust transfer process.	0.40
08/12/20	JD	Meeting with J. Lowne, K. Gadski, D. Rosen, M. Ronning (all Purdue), R. Schnitzler, T. Melvin, J. Turner (PJT) re: Adhansia business plan.	0.70
08/12/20	JD	Call with J. Turner (PJT) re: Adhansia business plan.	0.30
08/12/20	JD	Review draft updated Adhansia forecast presentation materials.	0.80
08/12/20	JD	Review management comments to draft Adhansia slides.	0.30
08/12/20	JD	Call with J. Lowne (Purdue) re: Adhansia business plan.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/12/20	JD	Review and process Nalmafene report.	0.30
08/12/20	JD	Review and update the latest Suboxone draft memo.	0.40
08/12/20	ADD	Compile material contracts for review by Purdue and Davis Polk.	1.30
08/12/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Review approved documents and upload materials to Project Catalyst VDR	1.20
08/12/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	0.50
08/12/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to walk through changes in market/product level financials across management forecasts.	2.40
08/12/20	NAS	Correspondence with FTI and Province re: current state of Mundipharma diligence process.	0.60
08/12/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to walk through changes in market/product level financials across management forecasts.	2.40
08/12/20	GJK	Analyze and assess market comparisons compared to prior management and base case and potential upside scenario.	2.50
08/12/20	GJK	Coordinate follow up activities for Mundipharma diligence including letter from counsel.	1.00
08/13/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest case developments detailed on advisor group call.	0.30
08/13/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to complete review of changes from current and prior iterations of Mundipharma management business plan.	1.50
08/13/20	GJK	Call with J. Lowne, R. Aleali (both Purdue), J. O'Connell,	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		T. Melvin, G. Sim (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and planning call.	
08/13/20	GJK	Review Mundipharma June diligence files for support of cost of sales and S&P revisions.	2.20
08/13/20	NAS	Call with G. Koch (AlixPartners) re: latest case developments detailed on advisor group call.	0.30
08/13/20	NAS	Review mark-up to Mundi diligence letter provided by UCC.	0.30
08/13/20	LJD	Call with J. Lowne, R. Aleali (both Purdue), J. O'Connell, T. Melvin, G. Sim (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and planning call.	0.90
08/13/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to complete review of changes from current and prior iterations of Mundipharma management business plan.	1.50
08/13/20	NAS	Draft product/market diligence question list and supporting exhibits for Huron/Mundipharma.	1.90
08/13/20	ADD	Meeting with A. Nadeau, A. Soma, D. Lundie, R. Shamblen (Purdue), A. DePalma, K. McCafferty (AlixPartners) re: RT R&D Discussion.	1.30
08/13/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (Purdue) A. Gallogly K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	0.50
08/13/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: diligence tracking and	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		VDR updates.	
08/13/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/13/20	JD	Update professional fee actual amounts and 2020 forecast.	0.80
08/13/20	JD	Review monthly IMS data to be shared with creditors.	0.40
08/13/20	JD	Review and provide comments on June draft monthly flash report.	0.70
08/13/20	JD	Review correspondence from PJT and management re: costs of liability insurance post-emergence.	0.40
08/13/20	JD	Review comments from management re: latest distributor agreements.	0.30
08/13/20	JD	Correspondence with J. Lowne and D. Fogel (both Purdue) re: Suboxone fact sheet.	0.50
08/13/20	JD	Update Suboxone memo in advance of discussion with the UCC.	0.60
08/13/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: diligence tracking and VDR updates.	0.90
08/13/20	KM	Analysis re: transition planning for project Catalyst.	0.70
08/13/20	KM	Meeting with A. Nadeau, A. Soma, D. Lundie, R. Shamblen (Purdue), A. DePalma K. McCafferty (AlixPartners) re: RT R&D Discussion.	1.30
08/13/20	KM	Analysis re: working capital and inventory scenarios for project Catalyst.	1.30
08/13/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (Purdue) A. Gallogly K.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	
08/13/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/13/20	KM	Analysis re: R&D portfolio planning for Catalyst.	0.30
08/13/20	KM	Call with D. Lundie (Purdue) re: project Catalyst.	0.60
08/13/20	KM	Call with W. DiNicola, D. Fogel (Purdue) re: cost center detail schedules for Catalyst.	0.60
08/13/20	KM	Update VDR tracking and analyses re: project Catalyst.	0.90
08/13/20	KM	Analysis and response re: inquires to recently posted diligence documents.	1.60
08/14/20	KM	Call with third party re: project Catalyst diligence.	0.30
08/14/20	KM	Analysis re: key agreements and terms and impact on Catalyst options.	0.60
08/14/20	KM	Call with D. Lundie (Purdue) and R. Schnitzler (PJT) re: diligence and negotiation next steps.	1.00
08/14/20	KM	Coordinate RM/WIP/FG inventory analysis re: project Catalyst diligence.	1.40
08/14/20	KM	Analysis and document management re: environmental diligence for project Catalyst.	1.90
08/14/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst.	0.30
08/14/20	KM	Document approval and management re: benefits programs for project Catalyst.	0.70
08/14/20	KM	Analysis re: product mapping for tech transfer requirements.	0.80
08/14/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Catalyst bi-weekly update.	
08/14/20	KM	Analysis re: transition planning for project Catalyst.	0.90
08/14/20	JD	Call with E. Diggs, D. Lojac (both Davis Polk), T. Melvin (PJT), A. DePalma and J. DelConte (both AlixPartners) re: material contract review.	0.40
08/14/20	JD	Review and sort through list of material contracts in advance of material contract review call with Davis Polk.	1.40
08/14/20	JD	Call with M. Huebner, C. Robertson (Davis Polk), S. Birnbaum, D. Gentin Stock (both Dechert), J. Bragg (Skadden), J. Bucholtz (King & Spalding), J. O'Connell, T. Melvin (PJT), L. Donahue and J. DelConte (AlixPartners) re: next Monitor report.	0.50
08/14/20	JD	Call with R. Aleali (Purdue) re: Monitor report.	0.30
08/14/20	JD	Correspondence with Davis Polk re: Subutex.	0.30
08/14/20	JD	Review opioid forecasts and WAC details for OxyContin, Butrans and Hysingla per diligence request from Province. Correspondence with Province re: same.	0.80
08/14/20	JD	Review and provide comments on weekly cash by product reports for Purdue and Rhodes prior to sharing with creditor advisors.	0.40
08/14/20	JD	Review list of active insurance policies re: AHC request.	0.20
08/14/20	JD	Review special committee presentation re: OSR shared services agreement.	0.40
08/14/20	ADD	Research and compile active, material contracts and submit materials to Purdue contact for review.	2.20
08/14/20	ADD	Research sources of material contracts and identify potential documents for review.	2.50
08/14/20	ADD	Call with E. Diggs, D. Lojac (both Davis Polk), T. Melvin (PJT), A. DePalma and J. DelConte (both AlixPartners) re:	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		material contract review.	
08/14/20	HSB	Review OxyContin sales forecasts prepared in response to UCC advisors' request for OxyContin only scenario data (continued).	0.40
08/14/20	HSB	Review OxyContin sales forecasts prepared in response to UCC advisors' request for OxyContin only scenario data.	0.40
08/14/20	NAS	Draft follow-up market product-level questions for Mundipharma and send to Huron.	0.40
08/14/20	NAS	Build new cost structure adjustments for latest iteration of Mundipharma business plan model.	2.20
08/14/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: latest case developments and priorities moving forward.	0.30
08/14/20	LJD	Prepare for and attend call with M. Huebner, C. Robertson (Davis Polk), S. Birnbaum, D. Gentin Stock (both Dechert), J. Bragg (Skadden), J. Bucholtz (King & Spalding), J. O'Connell, T. Melvin (PJT), L. Donahue and J. DelConte (AlixPartners) re: next Monitor report.	0.60
08/14/20	GJK	Follow up and planning for outstanding diligence items and next steps for Mundipharma diligence.	2.00
08/14/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest case developments and priorities moving forward.	0.30
08/14/20	GJK	Outline outstanding key items and potential impact on diligence findings, brain storm potential walkthrough with groups.	1.50
08/17/20	GJK	Plan and coordination for Mundipharma diligence.	2.00
08/17/20	NAS	Finalize upload from first iteration of Mundipharma business plan model for base case cost structure.	1.80
08/17/20	NAS	Build Other Europe and Other LAM cost structure for markets outside of top 15 provided by Mundipharma.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/17/20	NAS	Conform Management Revisions product terminology across January and June files provided.	0.80
08/17/20	NAS	Check initial draft of Mundipharma business plan base case and resolve discrepancies.	2.10
08/17/20	NAS	Build preliminary Mundipharma business plan 2.0 P&L using certain cost data from 1.0 model.	0.90
08/17/20	HSB	Call with T. Matlock, A. Hendin (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte and H. Bhattal (both AlixPartners) re: tax analysis.	0.50
08/17/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR	0.70
08/17/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.30
08/17/20	ADD	Review and compile agreements for contract materiality analysis.	2.60
08/17/20	JD	Finalize LTRP analysis file to send across to Purdue HR team to double check numbers.	0.70
08/17/20	JD	Correspondence with Purdue re: professional fee payments.	0.20
08/17/20	JD	Call with S. Hinden (Willis Towers Watson), S. Brecher, E. Vonnegut (both Davis Polk), R. Aleali, C. DiStefano, K. Laurel (all Purdue) re: KEIP/KERP plans.	0.70
08/17/20	JD	Call with T. Matlock, A. Hendin (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte and H. Bhattal (both AlixPartners) re: tax analysis.	0.50
08/17/20	JD	Call with M. Huebner (Davis Polk) re: Suboxone discussion with UCC.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/17/20	JD	Review updated draft Adhansia board slides in advance of call.	0.60
08/17/20	JD	Meeting with J. Lowne, C. Landau, M. Kesselman (all Purdue), J. Turner, R. Schnitzler (both PJT) re: updated Adhansia projections.	0.90
08/17/20	JD	Review AHC advisor diligence questions re: updated OxyContin forecast. Review potential responses from UCC presentation.	0.60
08/17/20	JD	Review correspondence between Davis Polk and R. Aleali (Purdue) re: material contract review.	0.40
08/17/20	JD	Review listing of active insurance policies and correspondence with Purdue re: same.	0.30
08/17/20	KM	Meeting with D. Lundie, K. McCarthy (both Purdue), R. Schnitzler (PJT) and third party re: project Catalyst inquiries.	1.00
08/17/20	KM	Meeting with D. Fogel (Purdue) re: tech transfers for project Catalyst.	0.40
08/17/20	KM	Analysis re: product and API mapping for Catalyst.	1.10
08/17/20	KM	Call with D. Fogel (Purdue) re: tech transfers for project Catalyst.	0.40
08/17/20	KM	Product and API mapping re: project Catalyst.	0.80
08/17/20	KM	VDR and diligence tracking updates re: project Catalyst.	1.20
08/17/20	KM	Review supply agreements re: project Catalyst.	0.80
08/17/20	KM	Review supply agreements re: project Catalyst.	0.50
08/17/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR	0.70
08/17/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst APA schedules.	
08/17/20	KM	Manage VDR document re: material agreements.	0.50
08/17/20	KM	Call with R. Schnitzler (PJT) re: diligence follow up.	0.30
08/17/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.30
08/18/20	KM	Analysis and response re: additional diligence requests.	0.40
08/18/20	KM	Coordinate diligence and VDR requirements re: environmental inquiries for Catalyst.	0.80
08/18/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners), re: diligence status update.	0.30
08/18/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	0.30
08/18/20	KM	VDR and diligence tracking updates re: project Catalyst.	1.20
08/18/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst APA schedules.	0.80
08/18/20	KM	Planning for urgent diligence needs re: project Catalyst.	0.70
08/18/20	KM	Edit ACP map diligence document re: project Catalyst.	0.60
08/18/20	KM	Refine, edit and circulate ACP map re: project Catalyst.	1.30
08/18/20	KM	Call with D. Fogel (Purdue) re: API volume mapping and prioritization for Catalyst.	0.40
08/18/20	KM	Analysis re: API-customer-Product mapping for Catalyst.	0.40
08/18/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, K. Kolar, T. Delahant, D. McGuire, G. Sparta (all Purdue) re: API-	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Customer-Product mapping for Catalyst.	
08/18/20	KM	Analysis and response re: due diligence inquiries.	2.10
08/18/20	JD	Call with C. DeStefano (Purdue) re: KEIP / KERF calculations.	0.50
08/18/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners), re: diligence status update.	0.30
08/18/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	0.30
08/18/20	ADD	Review liquidation analysis and draft assumption for various accounts.	1.70
08/18/20	ADD	Call with D. Lojac, C. Robertson, E. Diggs (all Davis Polk), K. McCarthy, R. Aleali (both Purdue), J. Turner, T. Melvin (both PJT), A. DePalma and J. DelConte (both AlixPartners) re: material contract review.	0.80
08/18/20	NAS	Build roll-up tabs for 2.0 Mundipharma base case.	0.90
08/18/20	NAS	Incorporate adjustments to original Management Revisions data in Mundipharma business plan model.	1.30
08/18/20	NAS	Compare product/market-level COGS figures across Base and Management cases in Mundipharma business plan model.	1.80
08/18/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) to review initial draft of new Mundipharma Base Case.	0.90
08/18/20	NAS	Compare product/market-level S&P figures across Base and Management cases in Mundipharma business plan model.	2.40
08/18/20	NAS	Finalize revised cost structure for inclusion in Mundipharma Base Case.	0.80
08/18/20	LJD	Call with M. Huebner, E. Vonnegut, C. Robertson (all	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. DelConte, L. Donahue, H. Bhattal, G. Koch (all AlixPartners) re: weekly update and go forward planning call.	
08/18/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) to review initial draft of new Mundipharma Base Case.	0.90
08/18/20	GJK	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. DelConte, L. Donahue, H. Bhattal, G. Koch (all AlixPartners) re: weekly update and go forward planning call.	0.80
08/18/20	GJK	Walkthrough of model revisions and open items for slide updates.	2.00
08/18/20	GJK	Review non-top 15 market product breakouts from Mundipharma.	2.00
08/18/20	GJK	Review open diligence items and Mundipharma responses, plan for business review updates based on revised timetable from Mundipharma.	2.50
08/18/20	JD	Call with E. Vonnegut (Davis Polk) re: upcoming case progress.	0.10
08/18/20	JD	Call with M. Huebner (Davis Polk) re: distributable value calculations.	0.20
08/18/20	JD	Call with J. Lowne (Purdue) re: business plan refresh.	0.40
08/18/20	JD	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. DelConte, L. Donahue, H. Bhattal, G. Koch (all AlixPartners) re: weekly update and go forward planning call.	0.80
08/18/20	JD	Review forecasts to provide to Davis Polk for tax modeling purposes. Review audited financials re: same.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/18/20	JD	Review distributable value analysis and interim OxyContin updated business case.	0.60
08/18/20	JD	Call with D. Lojac, C. Robertson, E. Diggs (all Davis Polk), K. McCarthy, R. Aleali (both Purdue), J. Turner, T. Melvin (both PJT), A. DePalma and J. DelConte (both AlixPartners) re: material contract review.	0.80
08/18/20	JD	Review Monitor's second report.	0.70
08/18/20	JD	Review existing materials re: state by state sales information and managed care contract timing per Davis Polk request.	1.00
08/19/20	JD	Bridge UCC distributable value calculations back to updated business plan materials provided to date.	0.70
08/19/20	JD	Review and provide comments to management on the draft Board slides re: Adhansia and Opioid update.	2.20
08/19/20	JD	Correspondence with R. Aleali (Purdue) and Skadden re: sales by state and managed care renewals.	0.40
08/19/20	JD	Review letter from the UCC to mediation parties and the corresponding distributable value calculations.	0.50
08/19/20	JD	Review PJT edits and comments to draft Board slides.	0.30
08/19/20	JD	Review and check LTRP performance and pro forma calculations from J. Lowne and C. DiStefano (both Purdue).	0.80
08/19/20	JD	Review final responses to AHC OxyContin diligence questions prior to the call.	0.30
08/19/20	JD	Review Xtampza IMS data to be provided to the committee.	0.40
08/19/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review latest drafts of Mundipharma 2.0 Base Case.	1.10
08/19/20	GJK	Review and assess variances between Mundipharma	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		models and potential next steps.	
08/19/20	LJD	Review correspondence between debtors counsel and committee counsel	0.50
08/19/20	NAS	Apply adjustments from Mundipharma 1.0 model to base case in 2.0 model.	1.10
08/19/20	NAS	Investigate variances between management and base cases from Mundipharma 1.0 and 2.0 models.	1.70
08/19/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review latest drafts of Mundipharma 2.0 Base Case.	1.10
08/19/20	NAS	Analyze large journal entries included in Mundipharma source data.	1.30
08/19/20	NAS	Implement risk adjustments to Base Case in Mundipharma 2.0 model.	3.60
08/19/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	0.40
08/19/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners), re: date room and pending approvals.	0.50
08/19/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	0.40
08/19/20	KM	Analysis and ACP map diligence document re: project Catalyst.	0.80
08/19/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst weekly status updates.	0.70
08/19/20	KM	Analysis and coordination re: outstanding diligence requests.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/19/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne, P. Strassburger, B. Koch (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, (both Skadden) re: project Catalyst MSA review.	2.00
08/19/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners), re: date room and pending approvals.	0.50
08/19/20	KM	VDR and diligence tracking updates re: project Catalyst.	0.60
08/19/20	KM	Call with J. Doyle (Purdue) re: legal changes to support ACP document for Catalyst.	0.60
08/19/20	KM	Planning for urgent diligence needs re: project Catalyst.	0.30
08/19/20	KM	Analysis re: ACP anonymity for project Catalyst API and FD suppliers.	1.20
08/20/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	0.30
08/20/20	KM	Update and manage VDR tracker and Intralinks re: project Catalyst.	0.60
08/20/20	KM	Meeting with R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg, M. Sumner (all Skadden) re: MSA review.	1.10
08/20/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: APA review.	1.50
08/20/20	KM	Analysis re: proposed changes to terms in MSA from bidders.	0.60
08/20/20	KM	Call with D. Fogel (Purdue) re: APA issues.	0.10
08/20/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners), re: diligence status update.	0.20
08/20/20	KM	Analysis for third party mapping re: project Catalyst.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/20/20	KM	Analysis and response re: ACP mapping for Catalyst.	1.10
08/20/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: APA review cont'd.	2.00
08/20/20	KM	Update and refresh diligence tracking and management re: project Catalyst.	0.90
08/20/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	0.30
08/20/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners), re: diligence status update.	0.20
08/20/20	HSB	Call with J. Turner, T. Melvin (both PJT), H. Bhattal, J. DelConte (both AlixPartners) re: Adhansia planning.	0.40
08/20/20	NAS	Analyze line item detail underlying revised Mundipharma business plan model variances.	2.40
08/20/20	NAS	Send follow-up diligence question re: Mundipharma budget journal entries to Huron/Mundipharma.	0.30
08/20/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: priorities for revisions to Mundipharma business plan model and diligence report.	0.50
08/20/20	NAS	Incorporate revised allocations to build product category standalone P&Ls in Mundipharma business plan model.	2.70
08/20/20	NAS	Build roll-up and check functionality for standalone cases in Mundipharma business plan model and review takeaways.	1.70
08/20/20	LJD	Call with Ken Buckfire RE: case update.	0.40
08/20/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: priorities for revisions to Mundipharma business plan	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		model and diligence report.	
08/20/20	GJK	Assess risk adjustment impact on base case.	2.50
08/20/20	GJK	Review prior Mundipharma working capital information for potential changes to revised model.	2.40
08/20/20	GJK	Review corporate/non-commercial entity charges and variances to previous model.	2.00
08/20/20	JD	Review LTRP and AIP details from Purdue HR for purposes of KEIP/KERP calculations.	1.60
08/20/20	JD	Review correspondence from PJT and management re: bridge of April business plan to latest business plan refresh with respect to total distributable value.	0.50
08/20/20	JD	Call with J. Lowne (Purdue) re: business plan refresh and Project Catalyst.	0.30
08/20/20	JD	Call with J. Turner, T. Melvin (both PJT), H. Bhattal, J. DelConte (both AlixPartners) re: Adhansia planning.	0.40
08/20/20	JD	Review insurance recovery presentation from Gilbert.	0.80
08/20/20	JD	Review potential materials to provide to shareholder's re: updated business plan. Correspondence re: same.	0.70
08/20/20	JD	Correspondence with management and PJT re: OxyContin AG modeling in Rhodes forecast.	0.40
08/20/20	JD	Update latest professional fee tracker and forecast for 2020	0.30
08/20/20	JD	Review revised draft Board slides prior to finalizing and sending them out as prereads.	0.60
08/21/20	JD	Call with M. Florence, J. Bragg (both Skadden), T. Melvin, G. Sim (both PJT), J. DelConte, A. DePalma (both AlixPartners), W. Shank, R. Aleali, M. Kesselman (all Purdue) re: managed care contracts.	0.80
08/21/20	JD	Call with C. DeStefano (Purdue) re: KEIP/KERP	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		calculations.	
08/21/20	JD	Correspondence with management and Davis Polk re: suboxone donations.	0.60
08/21/20	JD	Review initial Betadine Gargle store list and sales date.	0.30
08/21/20	JD	Review final mediation letter sent to all parties in response to the UCC letter.	0.30
08/21/20	JD	Review draft mark-ups re: Project Catalyst materials.	1.20
08/21/20	JD	Review correspondence from PJT and Davis Polk re: distributable value bridge.	0.70
08/21/20	GJK	Review updates to model product category projections.	2.00
08/21/20	GJK	Plan for report revisions based on current diligence status and model updates.	2.00
08/21/20	LJD	Review and comment on response to fee examiner	0.50
08/21/20	LJD	Review and comment on response letter for mediation parties	0.30
08/21/20	NAS	Build check functionality for Base/Adjusted cases of Mundipharma business plan model.	2.40
08/21/20	NAS	Compare new Mundipharma Base/Adjusted standalone cases with prior iteration of model and note takeaways.	0.80
08/21/20	ADD	Call with M. Florence, J. Bragg (both Skadden), T. Melvin, G. Sim (both PJT), J. DelConte, A. DePalma (both AlixPartners), W. Shank, R. Aleali, M. Kesselman (all Purdue) re: managed care contracts.	0.80
08/21/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/21/20	KM	Analysis of shared services and intercompany transactions re: project Catalyst.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/21/20	KM	Analysis of supply agreements and payables re: project Catalyst.	1.60
08/21/20	KM	Analysis and review of shared services re: project Catalyst.	0.90
08/21/20	KM	Analysis and responses re: environmental diligence inquiries.	0.60
08/21/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/21/20	KM	Meeting with R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg (all Skadden), Noramco diligence team re: APA/MSA submission review.	1.50
08/21/20	KM	Prepare for APA/MSA submission review.	0.20
08/21/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: APA review.	0.80
08/21/20	KM	Analysis and coordination re: outstanding diligence requests.	0.70
08/22/20	JD	Correspondence with PJT re: Opioid only scenario wind down costs.	0.40
08/23/20	JD	Call with E. Vonnegut (Davis Polk) re: Suboxone donations.	0.20
08/23/20	JD	Correspondence with PJT re: Avrio business plan.	0.20
08/24/20	JD	Correspondence with management re: analysis of potential donations. Review cost benefit analysis of donation and underlying reasoning.	0.60
08/24/20	JD	Correspondence with team re: pension assumptions.	0.30
08/24/20	JD	Correspondence with Province re: E&Y expansion of	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		services.	
08/24/20	JD	Correspondence with J. Lowne and M. Kesselman (both Purdue) re: Nalmafene reporting.	0.30
08/24/20	JD	Call with R. Aleali (Purdue) re: donations.	0.40
08/24/20	GJK	Review of Malta 2.0 variances with direct allocations.	2.00
08/24/20	GJK	Review Mundipharma model updates.	2.50
08/24/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review new Mundipharma Base Case with Risk Adjustments.	0.80
08/24/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review changes in consolidated Mundipharma P&L from first to second iteration of business plan model.	0.80
08/24/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review changes in Mundipharma Analgesics standalone P&L from first to second iteration of business plan model.	0.60
08/24/20	GJK	Plan and coordinate for Mundipharma diligence.	1.00
08/24/20	NAS	Review new Purdue diligence files uploaded to data room.	0.50
08/24/20	NAS	Review new standalone P&Ls for Base Case with Risk Adjustments.	0.80
08/24/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review new Mundipharma Base Case with Risk Adjustments.	0.80
08/24/20	NAS	Review changes to consolidated P&L between first and second iterations of Mundipharma business plan model and identify drivers.	2.60
08/24/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review changes in consolidated Mundipharma P&L from first to second iteration of business plan model.	0.80
08/24/20	NAS	Analyze product-level changes between first and second iteration of Mundipharma business plan model and identify drivers.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/24/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review changes in Mundipharma Analgesics standalone P&L from first to second iteration of business plan model.	0.60
08/24/20	KM	Meeting with D. Fogel (Purdue), A. DePalma K. McCafferty (AlixPartners) re: PO-SOW-Contracts for RT used by RP or PPLP.	1.60
08/24/20	KM	Analysis re: procurement spend for TTM, 2018 and 2019 for project Catalyst.	2.40
08/24/20	KM	Analysis re: consolidation of all RT agreements and match to SAP spend analysis.	1.60
08/24/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	0.40
08/24/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: analysis of supply contracts.	1.10
08/24/20	KM	Analysis re: supply content tracking for project Catalyst.	0.20
08/24/20	KM	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting	1.50
08/24/20	KM	Analysis re: top suppliers and customers for 2018/2019 re: project Catalyst schedule and reps requirements.	2.10
08/24/20	ADD	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting	1.50
08/24/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/24/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: analysis of supply contracts.	1.10
08/24/20	ADD	Meeting with D. Fogel (Purdue), A. DePalma K. McCafferty (AlixPartners) re: PO-SOW-Contracts for RT used by RP or PPLP.	1.60
08/25/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	1.10
08/25/20	ADD	Call A. DePalma, J. DelConte (both AlixPartners), R. Aleali, B. Miller (both Purdue), C. Robertson (Davis Polk), and Skadden team re: Purdue Material contract analysis.	1.00
08/25/20	ADD	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: Catalyst contracts Schedule Meeting	1.00
08/25/20	KM	Meeting with D. Fogel, R. Shamblen, D. Lundie, J. Lowne (all Purdue), R. Schnitzler (PJT) re: inventory plans and impact on credit for Catalyst.	0.50
08/25/20	KM	Analysis re: RT inventory valuation by type for project Catalyst.	0.20
08/25/20	KM	Call with R. Shamblen (Purdue) re: technology transfer requirements for product portfolio.	0.30
08/25/20	KM	Analysis re: API-product qualification mapping and planning for project Catalyst.	0.60
08/25/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst.	0.20
08/25/20	KM	Analysis re: RT inventory valuation by type for project Catalyst.	0.20
08/25/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(PJT), M. Gibson, A. Gallogly, R. Schlossberg, M. Sumner (all Skadden) re: Catalyst proposals review.	
08/25/20	KM	Update diligence tracking and analyses re: project Catalyst.	0.40
08/25/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	1.10
08/25/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg, M. Sumner (all Skadden) re: Catalyst supply agreement.	0.50
08/25/20	KM	Analysis re: Rhodes Tech agreements for Catalyst.	0.30
08/25/20	KM	Call with D. Fogel (Purdue), J. Carlisle (Purdue) re: Wilson purchasing per Rhodes Technologies agreements.	0.70
08/25/20	KM	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: Catalyst contracts Schedule Meeting	1.00
08/25/20	KM	Review and gap analysis re: environmental diligence requests from Noramco for project Catalyst.	0.90
08/25/20	NAS	Compare and conform allocation methodology across first and second iterations of Mundipharma business plan model.	1.30
08/25/20	NAS	Discussions with G. Koch, N. Simon (both AlixPartners) to review detailed reconciliations across first and second iterations of Mundipharma management forecasts.	2.30
08/25/20	NAS	Build detailed bridge from first and second iterations of Mundipharma management forecasts for Net Sales line.	1.20
08/25/20	NAS	Build detailed bridge from first and second iterations of Mundipharma management forecasts for Cost of Sales	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		line.	
08/25/20	NAS	Build detailed bridge from first and second iterations of Mundipharma management forecasts for Other Revenue and Royalties Receivable lines.	0.80
08/25/20	LJD	Review and comment on Oxy and Adhansia slides for board presentation	0.70
08/25/20	GJK	Assess Mundipharma product category P&Ls.	2.00
08/25/20	GJK	Review variances in product categories based on Mundipharma June model.	2.50
08/25/20	GJK	Discussions with G. Koch, N. Simon (both AlixPartners) to review detailed reconciliations across first and second iterations of Mundipharma management forecasts.	2.30
08/25/20	JD	Call A. DePalma, J. DelConte (both AlixPartners), R. Aleali, B. Miller (both Purdue), C. Robertson (Davis Polk), and Skadden team re: Purdue Material contract analysis.	1.00
08/25/20	JD	Review pre-read slides in advance of Board meeting on Thursday.	1.00
08/26/20	JD	Review Intellipharma IPD Analytics report prior to sharing with creditors.	0.30
08/26/20	JD	Prepare and provide draft responses to various questions from the monitor on the June flash report.	1.80
08/26/20	JD	Correspondence with Davis Polk re: questions from Province on the KEIP/KERP proposal.	0.50
08/26/20	JD	Correspondence with management and Davis Polk re: old license agreement diligence questions.	0.40
08/26/20	JD	Call with R. Aleali (Purdue) re: material contracts.	0.30
08/26/20	JD	Call with J. Lowne, R. Aleali (both Purdue), J. O'Connell, J. Turner (both PJT), M. Huebner, C. Robertson, S. Brecher, J. Crandall (all Davis Polk) re: pension plan	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		assumptions and status.	
08/26/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review detailed management forecast variance for Analgesics segment.	0.40
08/26/20	GJK	Review Management Revisions responses to diligence questions.	1.00
08/26/20	GJK	Review Mundipharma variances and open questions, planning for report update.	2.00
08/26/20	GJK	Review product category variances and bridge to Malta 1.0 and May Management Case.	2.00
08/26/20	NAS	Build summary variances between versions of Mundipharma management forecasts for all individual product categories.	1.10
08/26/20	NAS	Build detailed reconciliations across Mundipharma management forecasts for Deductions line items.	1.50
08/26/20	NAS	Build detailed reconciliations across Mundipharma management forecasts for Selling & Promotion, Medical Affairs, and General & Administrative line items.	1.70
08/26/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review detailed management forecast variance for Analgesics segment.	0.40
08/26/20	NAS	Review new diligence files uploaded to Purdue data room.	0.40
08/26/20	NAS	Finalize detailed reconciliation file covering different versions of Mundipharma management forecasts.	1.10
08/26/20	NAS	Add toggle functionality for Journal entries to Mundipharma business plan model.	1.30
08/26/20	KM	Analysis of Rhodes Tech MSA re: contracts sharing between PPLP entities.	0.40
08/26/20	KM	Call with third party re: shared services diligence	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		inquiries.	
08/26/20	KM	Meeting with T. Delehant, D. Fogel (both Purdue) re: Rhodes Pharma tech transfer requirements for project Catalyst.	0.80
08/26/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: APA/MSA review.	1.50
08/26/20	KM	Call with D. Fogel (Purdue) , J. Lowne (Purdue), R. Schnitzler (PJT) re: project Catalyst proposal savings review for PPLP Board meeting.	0.50
08/26/20	KM	Analysis re: transition services for project Catalyst.	1.00
08/26/20	KM	Call with R. Schnitzler (PJT) and third party re: APA and MSA feedback for project Catalyst.	0.50
08/26/20	KM	Analysis re: inventory transition planning for project Catalyst.	0.40
08/26/20	KM	Call with D. Fogel (Purdue) re: inventory valuation for APA.	0.60
08/26/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/26/20	KM	Analysis re: environmental due diligence inquiries.	0.60
08/26/20	KM	Analysis, documentation and review re: APA rep Section 3.21 for project Catalyst.	1.70
08/26/20	KM	Analysis re: quality agreements currently in place.	0.50
08/26/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst contract analysis.	1.50
08/26/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	
08/26/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst contract analysis.	1.50
08/27/20	ADD	Analyze material Purdue agreements and create a tracker for client review.	2.50
08/27/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.30
08/27/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status.	0.20
08/27/20	KM	Analysis re: environmental due diligence inquiries.	0.20
08/27/20	KM	Analysis re: PPLP and Rhodes Pharma tech transfer planning for Catalyst transition.	1.10
08/27/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status.	0.20
08/27/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst supply agreement discussion.	1.70
08/27/20	KM	Analysis and document summary re: environmental due diligence requests and reporting for Catalyst.	1.50
08/27/20	KM	Participation in PPLP Board Meeting re: project Catalyst update.	1.00
08/27/20	KM	Analysis and document creation re: APA Schedule A amendments.	0.70
08/27/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re:	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Catalyst status update meeting.	
08/27/20	KM	Call with D. Fogel (Purdue) re: PPLP and Rhodes Pharma tech transfer planning for Catalyst transition.	0.30
08/27/20	NAS	Build product category and region-level breakdowns of variance between Mundipharma management forecasts for Cost of Sales line item.	1.30
08/27/20	NAS	Discussions with G. Koch, N. Simon (both AlixPartners) to review Mundipharma management forecast product category variances and note takeaways.	1.60
08/27/20	NAS	Build product category and region-level breakdowns of variance between Mundipharma management forecasts for Selling & Promotion line item.	0.90
08/27/20	NAS	Build product category and region-level breakdowns of variance between Mundipharma management forecasts for General & Administrative line item.	1.40
08/27/20	LJD	Partial participation in PPI board meeting.	4.20
08/27/20	LJD	Review agenda and board materials	0.30
08/27/20	GJK	Assess risk adjustment shifts based on product category variances.	2.50
08/27/20	GJK	Discussions with G. Koch, N. Simon (both AlixPartners) to review Mundipharma management forecast product category variances and note takeaways.	1.60
08/27/20	GJK	Review Mundipharma variances and potential adjustments to base cases.	2.00
08/27/20	JD	Participate in PPI Board meeting.	5.00
08/27/20	JD	Review Board pre-reads prior to Board meeting.	0.50
08/27/20	JD	Call with R. Schnitzler (PJT) re: Project Catalyst.	0.30
08/27/20	JD	Correspondence with Davis Polk re: UCC KEIP/KERP requests.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/27/20	JD	Review validation files from D. Warren (Purdue) re: compensation arrangement information.	0.30
08/27/20	JD	Review initial draft list of material contracts from A. DePalma (AlixPartners). Make edits and provide comments re: same.	0.60
08/27/20	JD	Review updated bridge analyses from management for the fully updated business plan refresh.	1.00
08/28/20	JD	Correspondence with Davis Polk and PJT re: request for updated financial projection information from the NCSG. Review materials posted to the data room to be responsive.	0.60
08/28/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC catch up.	0.20
08/28/20	JD	Call with J. Lowne (Purdue) re: KEIP/KERP declaration.	0.40
08/28/20	JD	Call with J. O'Connell, J. Turner, R. Schnitzler (all PJT) and M. Cola (Board member) re: business plan refresh follow ups.	0.60
08/28/20	JD	Begin work on pulling together a summary wage file that includes all historical wage information as well as future AIP/LTRP/Retention payments by employee per UCC request.	2.80
08/28/20	JD	Finalize pulling together initial draft comprehensive wage tracker in response to UCC request.	1.90
08/28/20	GJK	Walkthrough of latest Mundipharma updated model.	2.00
08/28/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC catch up.	0.20
08/28/20	GJK	Review Mundipharma responses to country diligence questions.	0.30
08/28/20	GJK	Review open diligence questions.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/28/20	LJD	Debrief call with Ken Buckfire (board member) following PPI board meeting.	0.40
08/28/20	NAS	Revise Mundipharma model to incorporate Foundation product terminology to product/region/market metrics.	1.30
08/28/20	KM	Analysis edits and review re: MSA and APA for third party negotiations.	0.90
08/28/20	KM	Analysis re: materials agreements for project Catalyst.	1.10
08/28/20	KM	Call M. Gibson, A. Gallogly (both Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting	3.10
08/28/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: material agreements.	0.20
08/28/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst.	0.30
08/28/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.30
08/28/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst update.	1.00
08/28/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.30
08/28/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: material agreements.	0.20
08/28/20	ADD	Call M. Gibson, A. Gallogly (both Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting	3.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/29/20	ADD	Review and update project Catalyst contract materiality analysis in preparation for client review.	1.60
08/29/20	KM	Analysis re: API pricing schedules for APA.	0.30
08/29/20	KM	Debrief session with D. Lundie, J. Lowne, K. McCarthy, R. Aleali (all Purdue), R. Schnitzler (PJT), M. Gibson (Skadden), and third party diligence team re: project Catalyst discussion.	1.50
08/29/20	KM	Call with D. Lundie (Purdue), J. Lowne, K. McCarthy (Purdue), R. Schnitzler (PJT), M. Gibson (Skadden), and third party re: project Catalyst APA and MSA negotiations.	1.00
08/29/20	KM	Analysis re: API pricing schedules for APA.	0.10
08/29/20	KM	Call with D. Lundie (Purdue), J. Lowne, K. McCarthy (Purdue), R. Schnitzler (PJT), M. Gibson (Skadden) re: project Catalyst prep call for third party discussion.	0.90
08/30/20	KM	Analysis re: API pricing schedules for APA.	0.40
08/30/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst contract analysis review.	0.80
08/30/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst contract analysis review.	0.80
08/30/20	JD	Review and edit draft employee wage tracker given comments from management.	0.70
08/30/20	JD	Correspondence with management re: open KEIP / KERP items.	0.50
08/31/20	JD	Review updated compensation validation files from D. Warren (Purdue).	0.70
08/31/20	JD	Prepare attrition analysis for J. Lowne (Purdue).	1.10
08/31/20	JD	Update source files and wage tracker for comments from	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		C. DeStefano (Purdue). Correspondence with C. DeStefano (Purdue) re: same.	
08/31/20	JD	Review and edit final material contract analysis from A. DePalma (AlixPartners). Send around to internal Purdue group for review and discussion.	0.60
08/31/20	JD	Review analysis of historical termed employees from Purdue from 2017 to present. Cross reference against existing analyses and review for omissions. Correspondence with Purdue HR team re: same.	0.80
08/31/20	JD	Correspondence with D. Consla (Davis Polk) re: KEIP/KERP motion and outstanding diligence items.	0.40
08/31/20	JD	Review and edit latest wage tracker for latest information. Send around to internal group for review.	0.60
08/31/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners) to review variances between Base Cases in different versions of Mundipharma model and key drivers.	2.40
08/31/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners) to review changes in projected Mundipharma Selling & Promotion expense and underlying methodology.	2.80
08/31/20	GJK	Review of Mundipharma Sales and Promotion drivers.	1.80
08/31/20	GJK	Update commentary for Mundipharma consolidated bridge.	0.50
08/31/20	GJK	Review of updates EBITDA drivers in Mundipharma model.	1.00
08/31/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) to review changes in projected Mundipharma Selling & Promotion expense and underlying methodology.	2.80
08/31/20	NAS	Review new Mundipharma diligence responses provided by Huron.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/31/20	NAS	Build consolidated Base Case to Base Case variance across first and second iteration of Mundipharma models.	0.60
08/31/20	NAS	Draft guide to drivers of Base Case to Base Case variances between versions of Mundipharma models.	1.00
08/31/20	NAS	Revise S&P in Mundipharma Base Case to project based on variable methodology (as opposed to fixed).	0.90
08/31/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) to review variances between Base Cases in different versions of Mundipharma model and key drivers.	2.40
08/31/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.20
08/31/20	ADD	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: Catalyst contracts Schedule Meeting.	0.60
08/31/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies agreements.	1.70
08/31/20	HSB	Reviewed UCC letter to Judge Drain regarding discovery undertaken by the UCC.	0.30
08/31/20	KM	Analysis re: employee retention for project Catalyst proposal.	0.90
08/31/20	KM	Analysis re: proposed retention by third party by role.	0.40
08/31/20	KM	Analysis re: supply agreements for project Catalyst.	0.90
08/31/20	KM	Review details of project Catalyst materials contracts.	0.90
08/31/20	KM	Analysis re: transition services and transfer costs for project Catalyst.	1.10
08/31/20	KM	Analysis re: quota and inventory management and	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		scenarios re: project Catalyst.	
08/31/20	KM	Call with R. Schnitzler (PJT) re: transition services net costs for project Catalyst.	0.30
08/31/20	KM	Analysis re: WIP inventory valuation for transfer to third party.	0.40
08/31/20	KM	Analysis and coordination re: outstanding diligence requests.	0.50
08/31/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: Catalyst document review.	1.40
08/31/20	KM	Analysis re: MSA pricing.	0.60
08/31/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.20
08/31/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies agreements.	1.70
08/31/20	KM	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: Catalyst contracts Schedule Meeting.	0.60
Total			632.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	73.10	515.00	37,646.50
Nate A Simon	109.10	515.00	56,186.50
Isabel Arana de Uriarte	1.20	690.00	828.00
Gabe J Koch	122.50	840.00	102,900.00
HS Bhattal	2.00	840.00	1,680.00
Jesse DelConte	105.90	950.00	100,605.00
Kevin M McCafferty	206.00	950.00	195,700.00
Lisa Donahue	12.90	1,195.00	15,415.50
Total Hours & Fees	632.70		510,961.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
08/17/20	ADD	Virtual working session A. DePalma and S. Lemack (both AlixPartners) to update liquidation analysis spreadsheet with new data	1.00
08/17/20	SKL	Virtual working session A. DePalma and S. Lemack (both AlixPartners) to update liquidation analysis spreadsheet with new data	1.00
08/18/20	SKL	Virtual working session A. DePalma and S. Lemack (AlixPartners) to review liquidation analysis spreadsheet and identify next steps.	1.50
08/18/20	ADD	Virtual working session A. DePalma and S. Lemack (AlixPartners) to review liquidation analysis spreadsheet and identify next steps.	1.50
08/19/20	ADD	Virtual working session with A. DePalma and S. Lemack (both AlixPartners) to review and update liquidation analysis assumptions	1.30
08/19/20	HSB	Review updated excel file with liquidation analysis for all debtor entities.	0.60
08/19/20	SKL	Virtual working session with A. DePalma and S. Lemack (both AlixPartners) to review and update liquidation analysis assumptions	1.30
08/20/20	SKL	Meeting with J. DelConte, HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) re: liquidation analysis and next steps	0.90
08/20/20	SKL	Prepare updated Purdue/Rhodes payroll breakout to the liquidation analysis and update the consolidated summary accordingly.	1.30
08/20/20	SKL	Finalize remaining updates to the latest liquidation analysis and distribute prior to today's liquidation meeting.	1.80
08/20/20	SKL	Prepare updated professional fee breakout to the	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
		liquidation analysis and update the consolidated summary accordingly.	
08/20/20	JD	Meeting with J. DelConte, HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) re: liquidation analysis and next steps.	0.90
08/20/20	HSB	Meeting with J. DelConte, HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) re: liquidation analysis and next steps	0.90
08/20/20	ADD	Meeting with J. DelConte, HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) re: liquidation analysis and next steps.	0.90
08/21/20	SKL	Continue to update the liquidation analysis based on the latest feedback provided and provided additional notes and detail behind the assumptions.	2.30
08/24/20	SKL	Continue to review and update underlying assumptions in the latest liquidation analysis.	1.40
08/24/20	SKL	Call with A. DePalma, S. Lemack (both AlixPartners) re: liquidation analysis next steps.	0.40
08/24/20	JD	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H. Bhattal, A. DePalma, G. Koch, R. Collura, S. Lemack and J. DelConte (all AlixPartners) re: state claim.	1.70
08/24/20	RC	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H. Bhattal, A. DePalma, G. Koch, R. Collura, S. Lemack and J. DelConte (all AlixPartners) re: state claim.	1.70
08/24/20	GJK	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
		Bhattal, A. DePalma, G. Koch, R. Collura, S. Lemack and J. DelConte (all AlixPartners) re: state claim.	
08/24/20	ADD	Call with A. DePalma, S. Lemack (both AlixPartners) re: liquidation analysis next steps.	0.40
08/24/20	ADD	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H. Bhattal, A. DePalma, G. Koch, R. Collura, S. Lemack and J. DelConte (all AlixPartners) re: state claim.	1.70
08/26/20	HSB	Review excel file with liquidation analysis for Purdue.	0.90
08/28/20	JD	Correspondence with management and Davis Polk re: ongoing settlement discussions.	0.30
Total			<u><u>29.00</u></u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: POR Development
Client/Matter # 012589.00107

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	6.80	515.00	3,502.00
Sam K Lemack	13.50	515.00	6,952.50
Gabe J Koch	1.70	840.00	1,428.00
HS Bhattal	2.40	840.00	2,016.00
Jesse DelConte	2.90	950.00	2,755.00
Richard Collura	1.70	1,090.00	1,853.00
Total Hours & Fees	29.00		18,506.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Executory Contracts
Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
08/06/20	JD	Review draft cure costs analysis.	0.20
08/24/20	ADD	Call with J. DelConte and A. DePalma (AlixPartners) re: material contracts.	0.30
08/24/20	JD	Call with J. DelConte and A. DePalma (AlixPartners) re: material contracts.	0.30
Total			<u><u>0.80</u></u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Executory Contracts
Client/Matter # 012589.00108

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	0.30	515.00	154.50
Jesse DelConte	0.50	950.00	475.00
Total Hours & Fees	0.80		629.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
08/03/20	SKL	Call with A. DePalma and S. Lemack (both AlixPartners) re: claims process status and determine next steps	0.40
08/03/20	ADD	Call with A. DePalma and S. Lemack (both AlixPartners) re: claims process status and determine next steps	0.40
08/04/20	ADD	Meeting with A. DePalma (AlixPartners) and S. Lemack (AlixPartners) to review and reconcile latest claims register provided by Prime Clerk.	2.20
08/04/20	SKL	Meeting with A. DePalma (AlixPartners) and S. Lemack (AlixPartners) to review and reconcile latest claims register provided by Prime Clerk.	2.20
08/04/20	SKL	Review and reconcile latest Prime Clerk claims register and prepare list of open items/questions for the Prime Clerk team.	2.20
08/05/20	SKL	Review and reconcile latest match updates provided and circulate updated match table for review.	2.20
08/05/20	SKL	Meeting with A. DePalma, S. Lemack (both AlixPartners) Update claims database and reconcile latest claims register provided by Prime Clerk.	2.10
08/05/20	ADD	Meeting with A. DePalma, S. Lemack (both AlixPartners) Update claims database and reconcile latest claims register provided by Prime Clerk.	2.10
08/06/20	JD	Correspondence with L. Donahue (AlixPartners) re: claims process.	0.20
08/06/20	JD	Call with B. Schrag (Prime Clerk) re: claims reconciliation process.	0.30
08/06/20	JD	Call with C. Robertson (Davis Polk) re: claims reconciliation process.	0.30
08/06/20	SKL	Continue review and reconciliation of the latest Prime Clerk claims register and provide updates list of open	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
		items and questions to the Prime Clerk team.	
08/06/20	BJF	Match vendor names for claims reconciliation.	2.80
08/06/20	BJF	Vendor matching for claims resolution.	2.40
08/07/20	BJF	Match vendor names for claims reconciliation.	2.80
08/07/20	BJF	Vendor matching for claims resolution.	1.70
08/07/20	SKL	Finalize import of scheduled liabilities into the claims database.	1.80
08/07/20	JD	Call with C. Robertson (Davis Polk) re: claims process.	0.20
08/10/20	JD	Review latest claims match table re: claims reconciliation process.	0.20
08/10/20	SKL	Review latest feedback re: payment info for UST and work with the AP team to prepare update for future payments.	0.60
08/10/20	SKL	Review the latest Prime Clerk claims register and prepare updated match table accordingly.	1.70
08/11/20	SKL	Call with S. Lemack and J. DelConte (both AlixPartners) re: claims process.	0.20
08/11/20	JD	Call with S. Lemack and J. DelConte (both AlixPartners) re: claims process.	0.20
08/13/20	BJF	Match vendor names for claims reconciliation.	2.80
08/13/20	BJF	Vendor matching for claims resolution.	2.40
08/13/20	BJF	Continue to match vendor names for claims reconciliation.	1.70
08/17/20	SKL	Review latest match updates provided by S. Betik (AlixPartners) and B. Ferguson (AlixPartners) and update the claims database accordingly.	2.00
08/18/20	SKL	Continue to review and reconcile the latest Prime Clerk claims register and update the claims database accordingly.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
08/24/20	SKL	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H. Bhattal, A. DePalma, G. Koch, R. Collura, S. Lemack and J. DelConte (all AlixPartners) re: state claim.	1.70
08/24/20	HSB	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H. Bhattal, A. DePalma, G. Koch, R. Collura, S. Lemack and J. DelConte (all AlixPartners) re: state claim.	1.70
08/26/20	ADD	Meeting with A. DePalma and S. Lemack (both AlixPartners) Update claims database and reconcile latest claims register provided by Prime Clerk.	1.20
08/26/20	SKL	Meeting with A. DePalma and S. Lemack (both AlixPartners) Update claims database and reconcile latest claims register provided by Prime Clerk.	1.20
08/27/20	SKL	Virtual Working Session with A. DePalma, S. Lemack (both AlixPartners) Update claims database and review new claims.	1.00
08/27/20	ADD	Virtual Working Session with A. DePalma, S. Lemack (both AlixPartners) Update claims database and review new claims.	1.00
Total			50.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Claims Process
Client/Matter # 012589.00109

Fee Recap:

Consultant	Hours	Rate	Amount
Barbara J Ferguson	16.60	315.00	5,229.00
Andrew D DePalma	6.90	515.00	3,553.50
Sam K Lemack	24.20	515.00	12,463.00
HS Bhattal	1.70	840.00	1,428.00
Jesse DelConte	1.40	950.00	1,330.00
Total Hours & Fees	43.90		24,003.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
08/03/20	ADD	Identity and review Rhodes Tech materials contracts for potential assignment.	2.80
08/03/20	ADD	Research agreements entered and updated since September 2019 for review and analysis.	1.30
08/03/20	ADD	Review outstanding diligence requests and follow up with outstanding items.	1.70
08/03/20	ADD	Review material Rhodes Tech relationships and compile corresponding agreements into a spreadsheet for review by external counsel and client.	2.70
08/04/20	ADD	Review compile corresponding agreements into a spreadsheet for review by external counsel and client and extract relevant data elements necessary for review.	2.70
08/04/20	ADD	Compare contract tracker to clients iContracts database to identify missing agreements.	2.90
08/04/20	ADD	Research and identify Rhodes Tech business development counter parties at request of Davis Polk to determine potential confidentiality issues.	1.80
08/05/20	ADD	Compile materials submitted in response to diligence requests for processing by Davis Polk's eDiscovery team.	2.30
08/06/20	ADD	Calculate Rhodes Tech cure costs for material entities and distribute spreadsheet for review	2.70
08/06/20	KG	Stage and process data. Perform quality control review of processed data. Export and import data into Relativity. Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	0.30
08/08/20	ADD	Compile contracts for review by external counsel and upload to the Project Catalyst data room	2.80
08/11/20	ADD	Review outstanding Project Catalysts diligence questions	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		and compile status update.	
08/12/20	ADD	Review outstanding supply contract and request approval to upload materials.	1.40
08/12/20	KG	Stage and process data for loading. Perform quality control review of processed data. Export and import data into Relativity. Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	2.20
08/13/20	ADD	Compile documentation in response to diligence requests in preparation for approval and upload to the data room.	2.60
08/13/20	ADD	Compile and upload approved contracts to data room for review by counter parties.	2.90
08/14/20	ADD	Compile material IT contracts for legal review and upload to the data room.	1.70
08/14/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: diligence status update	0.20
08/14/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: diligence status update	0.20
08/17/20	ADD	Review and compile materials submitted in response to project Catalyst Diligence request.	2.30
08/18/20	ADD	Compile and upload to data room documents submitted in response to Project Catalyst diligence requests.	2.40
08/18/20	KG	Stage and process data for loading. Perform quality control review of processed data. Export and import data into Relativity. Load third party production into Relativity. Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	2.40
08/19/20	ADD	Compile and prepare Project Catalyst diligence materials	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		for approval and release.	
08/20/20	ADD	Identify and compile material contracts for review and upload to the Project Catalyst data room.	3.20
08/20/20	ADD	Continue to identify and compile material contracts for review and upload to the Project Catalyst data room.	2.60
08/20/20	ADD	Compile and upload documents provided in response to Project Catalyst diligence request in preparation for legal review.	1.80
08/20/20	KG	Stage and process data for loading. Perform quality control review of processed data. Export and import data into Relativity. Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	1.20
08/21/20	ADD	Prepare approval trackers and request approval to release files compile to response to diligence request.	1.40
08/21/20	ADD	Compile and upload documents provided in response to Project Catalyst diligence request in preparation for legal review.	2.30
08/21/20	ADD	Identify and compile material contracts for review and upload to the Project Catalyst data room.	3.00
08/23/20	ADD	Identify and review Rhodes tech contracts for review by external legal counsel in preparation for production in the Project Catalyst data room.	2.70
08/24/20	ADD	Compile and upload project Catalyst diligence requests for external legal and client review prior to production.	2.20
08/25/20	ADD	Review and analyze Rhodes Tech contracts to understand and categorize material agreements.	2.30
08/26/20	ADD	Organize and upload Project Catalyst diligence items to the data room for third-party review	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
08/27/20	ADD	Prepare and upload project Catalyst diligence request for upload to the data room for review.	2.60
08/27/20	KG	Stage and process data for loading. Perform quality control review of processed data. Export and import data into Relativity. Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	1.20
08/28/20	ADD	Review and analyze Rhodes Tech contracts to understand and categorize material agreements.	2.60
08/28/20	ADD	Organize and upload Project Catalyst diligence items to the data room for third-party review	2.80
08/29/20	ADD	Review contract schedules Project Catalyst in preparation for submission for legal review.	1.80
08/30/20	ADD	Review and analysis of history of Rhodes Tech agreements by entity for Project Catalyst diligence request.	2.30
08/31/20	ADD	Compile items submitted in response to project Catalyst diligence questions and request approval to post materials.	1.20
08/31/20	ADD	Identify and research missing agreements for Project Catalyst contract schedules.	2.30
Total			87.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Special Projects
Client/Matter # 012589.00110

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	79.70	515.00	41,045.50
Kristina Galbraith	7.30	645.00	4,708.50
Kevin M McCafferty	0.20	950.00	190.00
Total Hours & Fees	87.20		45,944.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
08/01/20	MSM	Prepare professional fees for July 2020 fee statement.	3.10
08/02/20	MSM	Prepare professional fees for July 2020 fee statement.	2.90
08/04/20	JD	Correspondence with J. Lowne (Purdue) re: AlixPartners May invoice.	0.30
08/04/20	TB	Prepare June 2020 monthly fee statement and exhibits.	2.10
08/04/20	AML	Prepare professional fees for July 2020 fee statement.	2.00
08/05/20	AML	Prepare professional fees for July 2020 fee statement.	1.50
08/05/20	ESK	Review June monthly fee statement	0.30
08/06/20	AML	Prepare professional fees for July 2020 fee statement.	3.50
08/07/20	AML	Email correspondence with J. DelConte (AlixPartners) re: Professional Fees	0.20
08/07/20	JD	Review final fee application to be filed with the court.	0.70
08/08/20	AML	Prepare professional fees for July 2020 fee statement.	3.00
08/13/20	LCV	Review Fee Examiner's Report of AlixPartners' Second Interim Fee Application	0.20
08/13/20	LCV	Draft exhibits and response to Fee Examiner re: AlixPartners' Second Interim Fee Application	2.40
08/13/20	JD	Initial review of second interim fee app review from the Fee Examiner.	0.80
08/14/20	LCV	Correspondence with E. Kardos (AlixPartners) re: response to Fee Examiner's Report of AlixPartners 2nd Interim Fee App	0.30
08/17/20	LCV	Emails with J. DelConte (AlixPartners) re: status of response to fee examiner for AlixPartners 2nd Interim Fee Application	0.10
08/17/20	JD	Edit draft response to the fee examiner's interim report on AlixPartners 2nd interim fee application.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
08/18/20	LCV	Call with J. DelConte, E. Kardos and L. Verry (all AlixPartners) re: response to fee examiners report of AlixPartners 2nd Interim Fee Application	0.50
08/18/20	LCV	Emails with Travel Services and Engagement Accounting re: response to Fee Examiner's Report of AlixPartners 2nd Interim Fee Application	0.40
08/18/20	ESK	Call with J. DelConte, E. Kardos and L. Verry (all AlixPartners) re: response to fee examiners report of AlixPartners 2nd Interim Fee Application	0.50
08/18/20	JD	Call with J. DelConte, E. Kardos and L. Verry (all AlixPartners) re: response to fee examiners report of AlixPartners 2nd Interim Fee Application	0.50
08/18/20	JD	Finish review of fee examiner report and finish drafting initial draft response.	1.50
08/19/20	TB	Analyze expenses noted in the Fee Examiners' objection to second interim fee application.	0.50
08/20/20	ESK	Provide comments to UST objection to interim fee application	1.30
08/20/20	ESK	Emails to/from J. DelConte (AlixPartners) re: Review UST objection to interim fee application	0.30
08/20/20	ESK	Prepare response to UST objection to interim fee application	1.00
08/20/20	LCV	Emails with T. Brewer, C. Mosher, J. DelConte (all AlixPartners) re: to follow up on information for response to Fee Examiner's Report on AlixPartners 2nd Interim Fee Application	0.20
08/20/20	JD	Correspondence with Concur and accounting re: flight details re: fee examiner questions.	0.60
08/21/20	JD	Finalize draft Fee Examiner response and send to L. Donahue (AlixPartners) for final review.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
08/21/20	ESK	Provide comments to UST objection to interim fee application	1.30
08/21/20	ESK	Emails to/from J. DelConte (AlixPartners) re: Review UST objection to interim fee application	0.30
08/24/20	JD	Review final response to the fee examiner and send across to D. Klauder (Bielli & Klauder).	0.40
08/24/20	JD	Review response from the fee examiner. Correspondence with L. Donahue and E. Kardos (both AlixPartners) re: same.	0.40
08/25/20	JD	Begin review of July fee statement.	1.10
08/26/20	ESK	Review proposed interim fee order	0.20
08/28/20	JD	Continue review of July fee application.	1.40
Total			38.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Fee Recap:

Consultant	Hours	Rate	Amount
Andrea M LeBar	10.20	375.00	3,825.00
Melanie McCabe	6.00	415.00	2,490.00
Tammy Brewer	2.60	450.00	1,170.00
Laurie C Verry	4.10	510.00	2,091.00
Elizabeth S Kardos	5.20	710.00	3,692.00
Jesse DelConte	10.50	950.00	9,975.00
Total Hours & Fees	38.60		23,243.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Court Hearings
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
08/26/20	JD	Participate telephonically in court hearing.	1.60
08/26/20	NAS	Partial attendance of telephonic court hearing.	0.50
08/26/20	HSB	Attend telephonic court hearing.	1.60
Total			3.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Court Hearings
Client/Matter # 012589.00114

Fee Recap:

Consultant	Hours	Rate	Amount
Nate A Simon	0.50	515.00	257.50
HS Bhattal	1.60	840.00	1,344.00
Jesse DelConte	1.60	950.00	1,520.00
Total Hours & Fees	3.70		3,121.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/02/20	RC	Review and provide comments related to tax distribution support compiled in response to requests from the UCC.	1.40
08/03/20	RC	Review distribution analysis and respond to questions from Davis Polk.	0.50
08/03/20	RC	Review additional information related to tax distribution support.	1.00
08/03/20	RC	Review documents gathered in responses to the UCC's request for tax related information.	0.70
08/03/20	SJC	Analyze and review support for 2009 tax distributions.	1.00
08/03/20	SJC	Pull support for 2016 Rhodes distributions.	0.50
08/03/20	SJC	Pull support for 2012 ex us distributions.	3.50
08/03/20	SJC	Review support for and analyzing 2012 ex us distributions.	2.50
08/03/20	FOS	Call with M. Rule, F. Silva, and A. DePalma (all AlixPartners) re: UCC information requests on cash transactions.	0.50
08/03/20	FOS	Prepare Report 1B documentation re: UCC information requests.	1.00
08/03/20	MFR	Call with M. Rule, F. Silva, and A. DePalma (all AlixPartners) re: UCC information requests on cash transactions.	0.50
08/03/20	MFR	Review and analysis of supporting data and documentation for Report 1B re: UCC information requests.	1.50
08/03/20	ADD	Call with M. Rule, F. Silva, and A. DePalma (all AlixPartners) re: UCC information requests on cash transactions.	0.50
08/04/20	MFR	Review and analysis of supporting data and documentation for Report 1B re: UCC information	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		requests.	
08/04/20	FOS	Prepare Report 1B documentation re: UCC information requests.	4.00
08/04/20	SJC	Review support for and analyzing 2012 ex us distributions.	1.50
08/04/20	SJC	Pull support for 2012 partner distributions.	3.50
08/04/20	SJC	Review and redact documents from Finance Folder(s) in preparation for processing an upload to data room.	3.00
08/04/20	RC	Review additional years of tax distribution support in response to requests from the UCC.	1.20
08/04/20	RC	Review documentation related to tax information in response to requests from the UCC.	0.90
08/05/20	RC	Review distributions related support documentation.	1.40
08/05/20	SJC	Pull support for 2015 Rhodes distributions.	0.50
08/05/20	SJC	Analyzing support for 2012 Partner Distributions.	2.50
08/05/20	SJC	Pull support for 2010 ex us distributions.	2.00
08/05/20	SJC	Review and redact documents from David Fogel folder in preparation for processing an upload to data room.	1.00
08/05/20	MFR	Review and analysis of supporting data and documentation for Report 1B re: UCC information requests.	2.20
08/06/20	MFR	Review and analysis of supporting data and documentation for Report 1B re: UCC information requests.	2.00
08/06/20	SJC	2010 ex us distribution analysis.	3.00
08/06/20	SJC	2010 Partner distribution analysis and pulling documentation from SAP.	3.00
08/06/20	SJC	Review and redact documents from Finance Folder(s) in	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		preparation for processing an upload to data room.	
08/06/20	RC	Review support documentation related to tax calculations.	1.00
08/07/20	RC	Review additional documentation related distributions gathered in response to the UCC's request.	0.80
08/07/20	SJC	Review and redact documents from David Fogel folder in preparation for processing an upload to data room.	1.50
08/07/20	SJC	2012 Partner distribution analysis and pulling documentation from SAP.	1.00
08/07/20	SJC	Review of 2010 ex us distribution analysis.	2.00
08/07/20	SJC	Review 2012 Partner distribution analysis.	1.50
08/07/20	MFR	Review and analysis of supporting data and documentation for Report 1B re: UCC information requests.	1.60
08/10/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	2.70
08/10/20	SJC	Pull and organize support for 2017 non-tax distributions for data room.	3.50
08/10/20	SJC	2008 Partner distribution analysis and pulling documentation from SAP.	1.00
08/10/20	SJC	Final review of 2012 distribution analysis.	0.50
08/10/20	SJC	2010 ex us and partner distribution analysis and review.	3.00
08/10/20	RC	Review and analysis of documentation related to tax information.	1.20
08/10/20	RC	Review support documentation related to non-tax distributions.	1.40
08/11/20	RC	Review additional tax information in connection with responding to the UCC's requests.	1.20
08/11/20	RC	Review and update status of special committee related	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		tasks.	
08/11/20	SJC	Pull support for 2016 ex us and partner distributions.	2.00
08/11/20	SJC	Update and pulling bank statements for 2016 ex us and partner distributions.	3.50
08/11/20	SJC	Pull and organize support for 2015 non-tax distributions for data room.	2.50
08/11/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	2.30
08/12/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	2.50
08/12/20	SJC	Pull support for 2016 ex us and partner distributions.	3.00
08/12/20	SJC	Update and pulling bank statements for 2016 ex us and partner distributions.	3.00
08/12/20	SJC	Pull and organize support for 2016 non-tax distributions for data room.	2.00
08/12/20	RC	Review non-tax distribution support documentation compiled in response to UCC's requests.	1.40
08/12/20	RC	Review documentation gathered in response to the UCC's request for tax related information.	0.40
08/13/20	RC	Review documents compiled in response to the UCC's requests related to distributions.	1.10
08/13/20	SJC	Pull and organize support for 2016 non-tax distributions for data room.	3.00
08/13/20	SJC	Continue to pull and organize support for 2016 non-tax distributions for data room.	3.00
08/13/20	SJC	Pull and organize support for 2013 non-tax distributions for data room.	2.00
08/13/20	MFR	Review of source data and work papers related to Report	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		1B and the UCC's request.	
08/14/20	MFR	Review and analysis of agreement between PPLP and Terramar. Correspondence with A. DePalma (AlixPartners) re: the same.	0.70
08/14/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	3.10
08/14/20	SJC	Pull and organize support for 2013 non-tax distributions for data room.	3.00
08/14/20	SJC	Pull and organize support for 2014 non-tax distributions for data room.	3.00
08/14/20	SJC	Continue to pull and organize support for 2014 non-tax distributions for data room.	1.50
08/14/20	RC	Review additional information in the BSA's data room and update related financial analyses.	0.70
08/14/20	RC	Review documentation provided by the Raymond Sackler family's counsel.	0.80
08/14/20	RC	Review documentation related to royalty information.	0.20
08/14/20	RC	Review documentation gathered in response to requests related to cash distributions.	0.60
08/14/20	HSB	Review excel file with liquidation analysis template, prepared by S. Lemack (AlixPartners).	0.40
08/17/20	RC	Review documents gathered in response to the UCC's request for support for non-tax distributions.	1.20
08/17/20	RC	Review support documentation related to Ex-US distributions.	1.50
08/17/20	RC	Review additional documentation related to non-tax distributions in response to the UCC's requests.	1.00
08/17/20	SJC	Pull and organize support for 2014 non-tax distributions for data room.	3.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/17/20	SJC	Pull and organize support for 2011 non-tax distributions for data room.	2.50
08/17/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	1.40
08/18/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	2.20
08/18/20	SJC	Pull and organize support for 2011 non-tax distributions for data room.	1.50
08/18/20	SJC	Pull and organize support for 2009 non-tax distributions for data room.	3.50
08/18/20	RC	Review and comment on information gathered in response to non-tax distribution related requests.	0.80
08/18/20	RC	Review additional tax-related information provided by TXP.	0.60
08/19/20	RC	Review documents related to the non-tax distribution requests.	1.00
08/19/20	RC	Review additional information provided by TXP's counsel.	0.80
08/19/20	RC	Continue to review non-tax distribution related documentation.	0.90
08/19/20	SJC	2008 Partner distribution analysis and pulling documentation from SAP.	3.50
08/19/20	SJC	Review of 2008 Partner distribution analysis and related supporting documents.	1.50
08/19/20	SJC	Pull and organize support for 2008 non-tax distributions for data room.	1.50
08/19/20	SJC	2010 Partner distribution and ex-us analysis and pulling documentation from SAP.	1.50
08/19/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/20/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	2.00
08/20/20	SJC	2010 Partner distribution and ex-us analysis and pulling documentation from SAP.	3.00
08/20/20	RC	Review documentation gathered in response to the UCC's request for tax information.	0.80
08/20/20	RC	Review support documentation related to non-tax distributions.	1.30
08/20/20	RC	Review information provided by the Sackler Family related to distributions.	1.20
08/21/20	RC	Review non-tax distribution related support documentation.	1.20
08/21/20	RC	Additional review of support documentation related to non-tax distributions.	1.50
08/21/20	RC	Review additional documentation related to distributions.	0.70
08/21/20	RC	Review documentation related to Ex-US distributions.	1.30
08/21/20	RC	Review support documentation gathered in response to the UCC's request for distribution related information.	1.00
08/21/20	RC	Review documentation from SAP gathered in response to requests from the UCC.	0.70
08/21/20	SJC	2016 Rhodes distribution analysis and pulling documentation from SAP.	2.00
08/21/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	1.80
08/23/20	RC	Review documentation compiled in response to requests from the UCC related to cash transfers of value report.	0.60
08/24/20	RC	Review support documentation related to the Ex-US Distributions.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/24/20	RC	Review support documentation related to the non-tax distributions and provide comments to review team.	1.30
08/24/20	RC	Additional review of support documentation related to Ex-US distributions.	1.10
08/24/20	RC	Review support documentation gathered in response to non-tax distribution requests from the UCC.	0.90
08/24/20	SJC	2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.00
08/24/20	SJC	2016 Rhodes distribution analysis and pulling documentation from SAP.	3.00
08/25/20	SJC	2016 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.00
08/25/20	SJC	2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.00
08/26/20	SJC	Call with R. Collura, A. DePalma and S. Canniff (all AlixPartners) re: various diligence requests and status update.	0.50
08/26/20	SJC	Prepare for internal meeting re: diligence requests status.	0.70
08/26/20	SJC	Review of 2016 Rhodes distribution analysis and related documentation.	0.60
08/26/20	SJC	2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.50
08/26/20	SJC	Continue 2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	2.00
08/26/20	RC	Call with R. Collura, A. DePalma and S. Canniff (all AlixPartners) re: various diligence requests and status update.	0.50
08/26/20	RC	Review and comment on non-tax distribution support documentation related to requests from the UCC.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/26/20	RC	Additional review of the non-tax distribution support documentation gathered in response to requests from the UCC.	1.10
08/26/20	ADD	Call with R. Collura, A. DePalma and S. Canniff (all AlixPartners) re: various diligence requests and status update.	0.50
08/27/20	RC	Review support documentation re: distribution requests made by the UCC.	1.30
08/27/20	SJC	2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.20
08/28/20	SJC	2013 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	2.00
08/28/20	SJC	2012 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	2.00
08/28/20	MFR	Review of source data and work papers related to Report 1B.	1.60
08/28/20	HSB	Review OCP report prepared by S. Lemack (AlixPartners).	0.50
08/31/20	FOS	Review documentation and SAP records re: 2019 MITS (UK) and PPLP IT Services Agreement.	2.00
08/31/20	FOS	Compose email to R. Collura and M. Rule (all AlixPartners) re: 2019 MITS (UK) and PPLP IT Services Agreement.	0.10
08/31/20	FOS	Correspondence with M. Rule (AlixPartners) re: 2019 MITS (UK) and PPLP IT Services Agreement.	0.30
08/31/20	SJC	2015 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	4.00
08/31/20	SJC	2018 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	0.50
08/31/20	SJC	2017 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/31/20	SJC	2009 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	1.20
08/31/20	SJC	2008 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	2.30
08/31/20	RC	Review questions from Province and setup team on additional next steps.	0.20
Total			223.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	1.00	515.00	515.00
Fernando O Silva	7.90	645.00	5,095.50
Sam J Canniff	134.00	645.00	86,430.00
HS Bhattal	0.90	840.00	756.00
Mark F Rule	34.40	910.00	31,304.00
Richard Collura	45.70	1,090.00	49,813.00
Total Hours & Fees	223.90		173,913.50

Exhibit B

AlixPartners, LLP

Summary and Detailed Description of AlixPartners' Expenses

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2
Re: Expense
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
05/13/20	Conference Calls Vendor: Vodafone Jesse DelConte	8.53
05/14/20	Conference Calls Vendor: Vodafone Jesse DelConte	31.50
05/18/20	Conference Calls Vendor: Vodafone Jesse DelConte	4.75
05/20/20	Conference Calls Vendor: Vodafone Ryan Sublett	15.45
05/21/20	Conference Calls Vendor: Vodafone Jesse DelConte	11.93
05/22/20	Conference Calls Vendor: Vodafone Jesse DelConte	5.45
05/22/20	Conference Calls Vendor: Vodafone Ryan Sublett	14.98
05/23/20	Conference Calls Vendor: Vodafone Jesse DelConte	14.87
07/01/20	Conference Calls Vendor: Jesse DelConte	4.59
07/02/20	Conference Calls Vendor: Jesse DelConte	2.79
07/02/20	Conference Calls Vendor: Jesse DelConte	19.92
07/09/20	Conference Calls Vendor: Jesse DelConte	44.27
07/24/20	Conference Calls Vendor: Jesse DelConte	13.39
07/30/20	Conference Calls Vendor: Vodafone Kevin McCafferty	0.27
07/31/20	Conference Calls Vendor: Vodafone Kevin McCafferty	1.29
08/04/20	Conference Calls Vendor: Vodafone Jesse DelConte	2.68
08/06/20	Conference Calls Vendor: Vodafone Jesse DelConte	23.36
08/10/20	Conference Calls Vendor: Vodafone Jesse DelConte	2.59
08/20/20	Conference Calls Vendor: Vodafone Jesse DelConte	3.38
08/20/20	Conference Calls Vendor: Vodafone Jesse DelConte	31.23
08/26/20	Legal Fees Jesse DelConte	70.00
Total Disbursements		327.22

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2127778-2
Re: Expense
Client/Matter # 012589.00150

Disbursement Recap:

Description	Amount
Legal Fees	70.00
Other	257.22
Total Disbursements	<u>327.22</u>